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Abstract 
Biopolymer microcarriers with an adapted size and/or a special coating can serve as a 
support for cell culture and/or differentiation when embedded in more complex 3D scaffold 
for local sustained delivery of biological signal. The programmed delivery of an appropriate 
active principle and/or growth factor can stimulate the grafted cells survival and 
differentiation and also modify the host microenvironment. Poly-lactic-co-glycolic acid 
(PLGA) is a well-know biocompatible and bioresorbable polymer which has received a great 
interest for the development of nanostructured microdevices to be used in tissue engineering; 
as a consequence, considerable scientific efforts have been made in the technology for the 
manufacturing these microdevices. Supercritical Emulsion Extraction (SEE) was recently 
proposed for the production of biopolymer microparticles starting from oil-in-water 
emulsions. This technology can improve the product quality because of the fast and selective 
extraction of the dispersed oily phase by using supercritical carbon dioxide (SC-CO2). 
However, until now, SEE was proposed in batch configuration, sharing with the traditional 
processes an intrinsically discontinuous operation, problems of batches reproducibility and 
process yield.  
In this study, by using a counter-current packed column, the SEE process was proposed 
in a Continuous operating mode (SEE-C) for the production of PLGA microcarrier loaded 
with bioactive signals. The new process design takes advantage of the large contact area 
between the SC-CO2 and emulsion allowing the production of microspheres with controlled 
and narrow size distributions in only few minutes. SEE-C operating parameters such as 
pressure, temperature and flow rate ratios were analyzed and the process efficiency was 
optimized in terms of size distribution of the recovered material and encapsulation efficiency, 
and it was compared with the one of SEE (in batch operation mode) and conventional 
evaporation/extraction technology. PLGA microparticles showed a mean particle size 
between 1-3 m (depending on the droplet sizes) with a standard deviation that was always 
smaller than that associated with particles produced by discontinuous processes. Single and 
double emulsions were successfully treated and the microdevices physico-chemical properties 
were investigated. Several bioactive compounds were selected to be encapsulated. In the case 
of retinyl acetate (RA), for example, several emulsions were tested and processed by SEE-C. 
Operating at 80 bar and 36°C, SEE-C produced PLGA/RA microspheres with mean sizes 
between 3.3 and 4.5 m with an excellent encapsulation efficiency (90%). The investigation 
12 
 
of the release profiles showed that all the RA was released in about 6 days when charged at 
2.7% w/w; whereas, only 40% and 10% of RA was released in the same period of time when 
the charge was 5.2% and 8.8% w/w, respectively. Release kinetics constants calculated from 
the experimental data by using a mathematical model were also proposed. PLGA 
microdevices loaded with bovine serum insulin, selected as a model of bioactive signal, were 
also produced. Different sizes (2 and 3 µm) or insulin charges (3 and 6 mg/g) and with a good 
encapsulation efficiency (60%) were obtained by SEE-C after processing of several water-oil-
water emulsions. These microcarriers were characterized in terms of insulin release profile in 
two different media (PBS and DMEM) and the diffusion and degradation constants were also 
estimated by using a mathematical model; a faster insulin release in the first two days was 
observed, followed by its sustained release for the subsequent 28 days. These microdevics 
were also used in a cultivation of embryonic ventricular myoblasts (cell line H9c2 obtained 
from rat) in a FBS serum free medium to monitor cell viability and growth in dependence of 
insulin released. Good cell viability and growth were observed on 3 µm microdevices loaded 
with 3 mg/g of insulin. PLGA microspheres loaded with growth factors (GFs) were also 
charged inside an alginate scaffold together with human Mesenchimal Steam Cells (hMSC), 
that are promising cell source for bone tissue engineering. The aim was to monitor the effect 
of the local release of these signals on cells differentiation. These “living” 3D scaffolds were 
incubated in a direct perfusion tubular bioreactor to enhance nutrient transport and exposing 
the cells to a given shear stress. Different GFs such as, h-VEGF, h-BMP2 and a mix of two 
(ratio 1:1) were loaded by processing several water-oil-water emulsions at 80 bar and 36°C, 
with an L/G ratio of 0.1 by SEE-C. Alginate beads were recovered from dynamic (tubular 
perfusion system bioreactor) and static culture at different time points (1
st
, 7
th
, 21
st
 days) for 
the analytical assays such as, live/dead; hematoxylin and eosin (H&E) staining; alkaline 
phosphatase; osteocalcin; osteopontin and Van Kossa Immunoassay. The immunoassay 
confirmed always a better cells differentiation in the bioreactor with respect to the static 
culture and revealed a great influence of the BMP-2 released in the scaffold on cell 
differentiation. Indeed, a more homogeneous calcium deposition and a larger cell cluster were 
observed in the beads charged with BMP-2. 
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Introduction 
 
Tissue engineering is an emerging multidisciplinary field involving biology, medicine, 
and engineering that is likely to revolutionize the ways we improve the health and quality of 
life for millions of people worldwide by restoring, maintaining, or enhancing tissue and organ 
function. In addition to having a therapeutic application, where the tissue is either grown in a 
patient or outside the patient and transplanted, tissue engineering can have diagnostic 
applications where the tissue is made in vitro and used for testing drug metabolism and 
uptake, toxicity, and pathogenicity. The foundation of tissue engineering for either therapeutic 
or diagnostic applications is the ability to exploit living cells in a variety of ways.  
Tissue engineering research includes the several areas such as, novel biomaterials that 
are designed to direct the organization, growth, and differentiation of cells in the process of 
forming functional tissue by providing both physical and chemical cues; methodologies for 
cells proliferation and differentiation to acquire the appropriate source of cells such as 
autologous (from the same individual to which they will be reimplanted), allogeneic (from 
donor of the same species), xenogeneic (from individuals of another species), stem cells 
(undifferentiated cells with the ability to give rise to different forms of specialized cells) and 
genetically engineered cells; engineering design and biomechanical aspects including 2D cell 
expansion, 3D tissue growth in bioreactors, vascularisation, mechanical signals regulating 
engineered tissues and efficacy and safety of engineered tissues. Informatics may also support 
tissue engineering helping the quantitative cellular image analysis, quantitative tissue 
analysis, in-silico tissue and cell modelling and digital tissue manufacturing, as well as, 
research that involves stem cells (human and non-human) in which they are isolated, derived 
or cultured for studying cellular differentiation or specialization in presence of specific 
growth factors, 3D biomaterials or mechanical solicitations. The term regenerative medicine 
is often used synonymously with tissue engineering, although those involved in regenerative 
medicine place more emphasis on the use of stem cells to produce tissues [1]. 
Tissue engineering utilizes living cells as engineering materials; they are often 
implanted or “seeded” into an artificial structure capable of supporting three-dimensional 
tissue formation. These structures, typically called scaffolds, are often critical, both ex vivo as 
well as in vivo, to influence their own microenvironments. Scaffolds usually serve the 
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following purposes: allow cell attachment and migration, deliver and retain cells and 
biochemical factors, enable diffusion of vital cell nutrients and expressed products and exert 
certain mechanical and biological influences to modify the behavior of the cell phase. To 
achieve the goal of tissue reconstruction, scaffolds must meet some specific requirements. A 
high porosity and an adequate pore size are necessary to facilitate cell seeding and diffusion 
throughout the whole structure of both cells and nutrients. Biodegradability is often an 
essential factor since scaffolds should preferably be absorbed by the surrounding tissues 
without the necessity of a surgical removal. The rate at which degradation occurs has to 
coincide as much as possible with the rate of tissue formation. Injectability is also important 
for clinical uses. Recent research on organ printing is showing how crucial a good control of 
the 3D environment is to insure reproducibility of experiments and offer better results. 
 
 
 
Figure I.1. Basic principles of Tissue Engineering. 
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Chapter 1. State of the Art 
 
1.1 Tissue engineering: top-down & bottom-up approaches 
The field of tissue engineering has emerged to fill the void where neither native 
physiology nor purely artificial implantable materials can sufficiently replace or repair these 
damaged tissues [2]. While tissues such as bone [3] or skin [4-5] can effectively repair a small 
injury given sufficient time, many tissues such as myocardium [6] and cartilage [7] do not 
regenerate properly without intervention. Traditional tissue engineering strategies typically 
employ a “top-down” approach, in which cells are seeded on a biodegradable polymeric 
scaffold [8-10]. In top-down approaches, the cells are expected to populate the scaffold and 
create the appropriate extracellular matrix (ECM) and micro-architecture often with the aid of 
perfusion, growth factors and/or mechanical stimulation [11].  
The bottom-up approach, also known as modular tissue engineering, aims to address the 
challenge of recreating bio-mimetic structures by designing structural micro-features to build 
modular tissues that can be used as building blocks to create larger tissues. These modules can 
be created in different ways, such as through self-assembled aggregation [12], 
microfabrication of cell-laden hydrogels [13], creation of cell sheets [14] or direct tissue 
printing [15]. Once created, these modules can be assembled into larger tissues through a 
number of methods such as random packing [16-17], stacking of layers [18] or directed 
assembly [19]. By mimicking native micro-structural functional units, bottom-up approaches 
aim to create more bio-mimetic engineered tissues. The historical roots of this modular 
approach trace back to microencapsulation techniques, such as encapsulating pancreatic islet 
cells in alginate gels for transplantation in diabetic rats [20]. Although these studies were not 
conceived as modular tissue engineering, each cell-containing microcapsule behaves as a 
tissue module performing a particular function. Current techniques for creating modular 
tissues draw from research in microencapsulation and micro-fabrication, as well as, traditional 
cell and tissue culture procedures. By creating modular tissues with more physiological 
micro-architectural features, bottom-up tissue engineering aims to provide more guidance on 
the cellular level to direct tissue morphogenesis. 
The major challenges to overcome in the future will be the potential integration of 
bottom-up techniques with more traditional top-down approaches to create more complex 
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tissues than are currently achievable using either technique alone by optimizing the 
advantages of each technique. Modular tissue engineering possesses immense potential for 
advancing the fields of tissue engineering while bringing us closer to the ultimate goal of 
creating clinically relevant engineered tissues for human implantation and the treatment of 
disease [21]. 
 
1.2 Materials for scaffolds fabrication  
Biopolymers are the materials mainly used for scaffolds in various tissue engineering 
applications. Poly-(glycolic acid) (PGA), poly-(lactic acid) (PLA), and their copolymers are a 
family of linear aliphatic polyesters, which are the most frequently used in tissue engineering. 
These polymers degrade through hydrolysis of the ester bonds. PGA is one of the most widely 
used scaffolding polymers. Because of its relatively hydrophilic nature, PGA degrades rapidly 
in aqueous solutions or in vivo, and loses mechanical integrity between two and four weeks. 
PLA is also widely used for scaffold fabrication. The extra methyl group in the PLA repeating 
unit (compared with PGA) makes it more hydrophobic, reduces the molecular affinity to 
water, and leads to a slower hydrolysis rate. It takes many months or even years for a PLA 
scaffold or implant to lose mechanical integrity in vitro or in vivo. To achieve intermediate 
degradation rates between PGA and PLA, various lactic and glycolic acid ratios are used to 
synthesize PLGA.  
Particularly, Poly-lactic-co-glycolic acid (PLGA, with a copolymer ratio of 75:25 or 
50:50) has received a great interest for the development of injectable micro-particulate 
devices [22]. For example, PLGA micro particles can be administered by in-situ injection to 
achieve a precise and localized drug delivery which is more effective in chemotherapy, 
hormone therapy, DNA/protein or vaccine delivery [23-26]. Moreover, PLGA micro particles 
with a specific size and distribution have also been proposed for the use in tissue engineering 
as building blocks of implantable 3D scaffolds offering benefits such as good morphology 
control and better versatility in the release kinetics of specific growth factors for cellular 
function orienting and directing or biodegradable support for cell culture and/or cell 
administration [27]. 
There are other linear aliphatic polyesters, such as poly-(-caprolactone) (PCL) and 
poly-(hydroxy butyrate) (PHB), which are also used in tissue engineering research. PCL 
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degrades at a significantly slower rate than PLA, PGA, and PLGA. The slow degradation 
makes PCL less attractive for general tissue engineering applications, but more attractive for 
long-term implants and controlled release applications. Natural polymers are also used such as 
proteins and polysaccharides. Collagen is a fibrous protein and a major natural extracellular 
matrix component. It has been used for various tissue regeneration applications [28]. 
 
1.3 Injectable scaffolds & Pharmacologically Active Microcarriers 
For some specific tissue regeneration, the cell therapy and the in-vivo approach will 
probably become a major therapeutic strategy in the coming years. Nevertheless, to overcome 
certain problems such as cell survival, lack of cell differentiation and integration in the host 
tissue a new tool described as pharmacologically active microcarriers (PAMs) have been 
described. PAMs are bioresorbable microparticles coated with cell adhesion molecules and 
presenting a controlled delivery of growth factor. In this configuration they may serve as a 
support for cell culture, survival and differentiation, as well as to influence their 
microenvironment. Indeed, the combined effect of growth factor and coating can influence the 
transported cells by promoting their survival and differentiation and favoring their integration 
in the host tissue after PAMs complete degradation. Furthermore, the released factor may also 
influence the microenvironment. Several studies indicated that PAMs could be a promising 
strategy for cell therapy of neurological diseases and could be employed in other situations 
with fetal cell transplants or with stem cells [29-30]. For example, PLGA-PAMs coated with 
adhesion molecules and loaded with nerve growth factor (NGF) and conveying PC12 cells, 
were produced and characterized. These cells showed the ability to differentiate into 
sympathetic-like neurons after adhering to PAM substrates in the presence of NGF and, can 
then, release large amounts of dopamine. Certain parameters such as, the size of the 
microcarriers, the conditions enabling the coating of the microparticles and the subsequent 
adhesion of cells have to be optimized to produce engineered microdevices. 
PLGA microspheres have been also reported as a moldable scaffold for cartilage tissue 
engineering [31-33]. For example, PLGA based cell carrier has been obtained with RGDS 
peptides immobilized by bonding with the gelatin molecules under the catalyzation of water 
soluble carbodiimide (EDAC). Chondrocytes were thus cultured to detect the applicability of 
the microspheres, as the injectable cell carriers. It is known that the RGD peptide family can 
bind with the integrins on cell membrane, thus facilitating cell adhesion. Cell adhesion is the 
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first event in which the anchorage-dependent cells come into contact with a substrate. Only 
after that event the cells can spread and proliferate. Since the gelatin contains also lots of 
bioactive domains including RGD peptides, the adopted strategy then results in more 
cytocompatible microcarriers which are suitable to attract and deliver live cells such as 
chondrocytes. PLGA/gelatin-RGDS microspheres revealed their applicability as chondrocyte 
microcarriers and as injectable scaffold for in vivo chondrogenesis [34]. 
Microspheres seeded with specific cells can be also considered as smaller building 
blocks in a recent approach [35]. For example, micrometric Tissue Precursors (microTPs) 
were obtained by dynamic cell seeding of bovine fibroblasts on porous gelatine microcarriers 
using a spinner flask bioreactor. During the dynamic seeding, cells adhered, proliferated and 
synthesized a thin layer of extracellular matrix (ECM) in and around the macroporous beads, 
generating the microTPs. The cells and ECM layer around the microTPs allowed their 
biological sintering via cell-cell and cell-matrix interaction after only a few days of dynamic 
seeding. The assembling ability of microTPs was exploited and the results obtained in this 
survey pave the way to realizing a 3-D dermal tissue equivalent by means of a bottom-up 
tissue engineering approach.  
 
1.4 Scaffold by conventional technologies: top-down approach 
In the top-down approach the scaffold is an artificial extracellular matrix which 
supports three-dimensional cellular tissue formation. It has to be characterized by an high 
porosity (≥ 90%), by a proper cell size and high interconnectivity (for uniform cell seeding 
and easy nutrients/metabolites diffusion); by biodegradability associated with mechanical 
integrity (to maintain the predesigned tissue structure) and it is also expected a positive 
interaction with cells, including enhanced cell adhesion, growth, migration, and differentiated 
function [36]. The most commonly used method for fabricating scaffolds for tissue 
engineering is the solvent casting and particulate leaching. This method involves mixing 
water-soluble salt (sodium chloride, sodium citrate) particles into a biodegradable polymer 
solution. The mixture is then cast into the mold of the desired shape. After the solvent is 
removed by evaporation or lyophilization, the salt particles are leached out to obtain a porous 
structure. The advantages of the method are the possibility of obtaining controlled porosity 
and interconnection degree. On the other hand, several post-treatments on the scaffolds are 
 19 
required to eliminate the residual solvents and the smooth wall usually obtained that are not 
suitable for the cellular growth [37].  
Emulsion freeze-drying technique was also used for the fabrication of highly porous 
PLGA scaffolds. The processing method consists of creating an emulsion by homogenization 
of a polymer solution (in an organic solvent) and water mixture, rapidly cooling the emulsion 
to lock in the liquid state structure, and removing the solvent and water by freeze-drying. 
Scaffolds with porosity greater than 90% and a cell size ranging from 20 to 200 µm can be 
fabricated with this method [38]. One important disadvantage of this technique is the closed 
cell structure obtained in the resulting matrix; moreover, it is not simple to control the cell 
size.  
Electrospinning is a fabrication process that uses an electric field to control the 
formation and deposition of polymer fibers onto a target substrate. In electrospinning, a 
polymer solution or melt is injected with an electrical potential to create a charge imbalance. 
At a critical voltage, the charge imbalance begins to overcome the surface tension of the 
polymer solution to form an electrically charged jet. The jet within the electric field is 
directed toward the ground target, during which time the solvent evaporates and fibers are 
formed. This electrospinning technique can fabricate fibrous polymer scaffolds with fiber 
diameters ranging from several microns down to several hundred nanometers [39]. 
Limitations to produce scaffold with this technique are: low mechanical strength and difficult 
in controlling cells shape and cells size.  
Rapid prototyping is a technology based on the advanced development of computer 
science and manufacturing industry. The main advantage of these techniques is their ability to 
produce complex products rapidly from a computer-aided design (CAD) model. One of these 
rapid prototyping techniques, called 3D printing, has been used to process biodegradable 
polymer scaffolds for tissue engineering applications [40]. This process generates components 
by ink-jet printing a binder on to sequential powder layers. The operation parameters such as 
the speed, flow rate, and drop position can be computer controlled to produce complex 3D 
polymer scaffolds. Biological agents, such as growth factors, can also be incorporated into the 
scaffolds in the printing process. However, the limitation of this method is that the resolution 
is determined by the jet size, which makes it difficult to design and fabricate scaffolds with 
fine microstructures. 
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Phase-separation techniques have been used to fabricate porous membranes for 
filtration and separation. Controlled phase separation processes, primarily thermally induced 
phase separation (TIPS), have been also explored for scaffolds fabrication [41]. This 
technique was recently utilized to fabricate biodegradable 3D polymer scaffolds. With this 
technique it is possible to obtain a fibrous structure with small pore size. On the other hand, 
the phase separation presents various problems such as, mean pore size obtained is often too 
small, long time of processing and post-treatments to eliminate the residual solvent are also 
necessary.  
Gas foaming process can be used to fabricate highly porous polymer foams without the 
use of organic solvents. Recently, also supercritical carbon dioxide (CO2) has been used as an 
agent for the formation of polymer foams. Solid polymer disks are exposed to high pressure 
CO2 to allow saturation of CO2 in the polymer. Thermodynamic instability is then created by 
rapidly releasing CO2 gas from the polymer system, followed by the nucleation and growth of 
gas bubbles in the material. Polymer sponges with a cell size of 100 µm and porosity up to 
93% can be fabricated using this technique. The disadvantage of this method is that it yields 
mostly a nonporous surface and closed-cell structure, with only 10–30% of interconnected 
cells. The porosity and inter-cell connectivity can be significantly improved by combining 
particulate leaching technique with the gas-foaming process although completely eliminating 
closed cells remains challenging [42]. 
One of the major challenges of bottom-up tissue engineering approach is to assemble 
modular tissues with specific micro-architectures into macroscale bio-mimetic engineered 
tissues. The challenge is to retain the micro-architecture and cellular behavior of modular 
tissues, while creating engineered tissues with robust mechanical properties to withstand 
clinical implantation and interact appropriately with the native tissues. Micro & nano 
particles sintering technology can be also considered a bottom-up approach rely upon the 
employment of biomaterials that integrate biodegradable scaffolds with growth factor delivery 
devices to better guide cellular activities and enhance tissue neogenesis. These bioactive 
scaffolds are recently obtained through the thermal assembly of protein activated PLGA or 
PCL microspheres and larger protein free microspheres obtained by emulsion evaporation 
technology. It is shown that the pore dimension, interconnectivity and mechanical properties 
in compression of the scaffold could be predefined by an appropriate choice of the size of the 
protein-free microparticles and sintering process conditions. These matrices offer the 
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possibility to concurrently modulate and control the size and extension of the porosity, 
mechanical properties and the spatial-temporal distribution of multiple bioactive signals [43].
 
The methods to produce microsphere-based scaffolds are: heat-sintering and solvent vapour 
treatment (dichloromethane) or solvent/non-solvent sintering method (acetone and ethanol 
treatment) or a non-solvent sintering technique (ethanol treatment); all of which involve 
exposure to elevated temperatures or organic solvents that may be a potential limitation to 
their pharmaceutical or medical applications. 
Additive photo-crosslink of cell-laden hydrogels technique uses 2D arrays of cells and 
ExtraCellular Matrix (ECM)/polymers as the building blocks to create tissues layer-by-layer 
[44-45]. Using additive photopolymerization, dual layer modular tissues were created to 
fabricate living tissues of cellular hydrogels for hepatic tissue engineering. While this 
technique successfully creates modular tissues with geometries similar to the native 
hepatocyte environment, one potential drawback of this technique is the inability to restrict 
the thickness of subsequent layers. Despite progress in using micro-fabrication techniques to 
improve the vascularization of engineered tissues this limitation is still present in many 
engineered tissues. In an alternative approach to creating capillary networks, a random 
packing of encapsulated modules technology was developed to create tortuous channels of 
perfusable modular tissues. Cylindrical, perfused tissues were created by assembling cell-
laden collagen units together within perfused tubing [46-47].  
Tissue printing deposits cells in small groups using similar technology to traditional 
printing systems. The advantage of this technique is the high potential level of control in cell 
and ECM placement and alignment to create engineered tissues with a wide array of 
properties and geometries. Replacing ink with cells suspended in liquid ECM or self 
assembled ECM mimics, a specific pattern is designed and printed onto a substrate, then the 
resultant cell aggregate is cultured to allow the cells and ECM to integrate into tissue 
structures [48-49]. While this technique could be effective in creating modular 2D tissues, one 
disadvantage of this technique is the impact on cell viability in the time elapsed between 
creation of subsequent tissue layers. Finally, one technique that has successfully addressed the 
insufficient mechanical properties and cell alignment in engineered modular tissues is cell 
sheet engineering, by creating sheets of cells under conditions that encourage ECM 
production. Engineered modular tissues, made using these techniques, have shown 
mechanical properties on the order of native tissues. Some potential limitations, however, are 
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the limited possible geometries that can be fabricated using sheets as well as reported leaking 
between layers indicating insufficient joining between them [50]. 
 
1.5 Biopolymer microdevices by conventional technologies: bottom up 
approach 
Several techniques can be used to prepare biopolymer microcarriers, but the solvent 
evaporation/extraction of emulsion (single, double or multiple) is the most widely used. In the 
most simplified case (i.e., the single emulsion processing) the process involves oil-in-water 
(o/w) emulsification. The polymer is first dissolved in a water immiscible, volatile organic 
solvent. The drug is then added to the polymer solution to produce a solution or dispersion of 
the active substance. This polymer-solvent-drug solution/dispersion is, then, emulsified (with 
appropriate stirring and temperature conditions) in a larger volume of water in presence of an 
emulsifier (as poly-vinyl alcohol, PVA) to yield an o/w emulsion. The emulsion is subjected 
to solvent removal by either evaporation or extraction process to harden the oil droplets [51]. 
In the former case, the emulsion is maintained at reduced pressure or at atmospheric pressure, 
with a low stir rate to enable the volatile solvent to evaporate. In the latter case, the emulsion 
is transferred into a large quantity of water (with or without surfactant) or other quench 
medium, into which the solvent associated with the oil droplets is diffused out. The solid 
microspheres obtained are, then, washed and collected by filtration, sieving, or centrifugation. 
They are dried under appropriate conditions or lyophilized.  
One of the disadvantages of the o/w emulsification method is the poor encapsulation 
efficiencies of moderately water-soluble and water-soluble drugs. The drug could diffuse out 
or partition from the dispersed oil phase into the aqueous continuous phase and 
microcrystalline fragments of the hydrophilic drugs can deposited on the microsphere surface 
and dispersed in the polymer matrix [52].  
The double (or multiple) emulsion processing is a water-in-oil-in-water (w/o/w) method 
and is best suited to encapsulate water-soluble drugs like peptides, proteins, and vaccines, 
unlike the o/w method which is ideal for water-insoluble drugs. A buffered or plain aqueous 
solution of the drug (sometimes containing a viscosity enhancer and/or stabilizing protein like 
gelatin) is added to an organic phase consisting of the polymer and an organic solvent with 
vigorous stirring to form the first microfine w/o emulsion. This emulsion is gently added with 
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stirring into large-volume water containing an emulsifier to form the w/o/w emulsion. The 
emulsion is, then, subjected to solvent removal by either evaporation or extraction process. 
The solid microspheres so obtained are then washed and collected by filtration, sieving, or 
centrifugation. These are then dried under appropriate conditions or are lyophilized to give the 
final free flowing microsphere product. It should be noted that the solvent evaporation process 
is similar to the extraction ones; i.e., the solvent must first diffuse out into the external 
aqueous dispersion medium before its evaporation. The rate of solvent removal by the 
extraction method depends on the temperature of quench water or other medium, ratio of 
emulsion volume to quench water/medium volume and the solubility characteristics of the 
polymer, the solvent and the dispersion medium. The rate of solvent removal by evaporation 
method strongly influences the characteristics of the final microspheres and it depends on the 
temperature, pressure, and the solubility parameters of the polymer, the solvent, and the 
dispersion medium [53]. Solvent evaporation has several drawbacks because it requires 
relatively high temperatures or reduced pressures and shows batch to batch reproducibility 
disturbances. Solvent extraction uses relatively large amounts of a second solvent with the 
subsequent problem of solvent mixtures recovery. Both processes, also, require quite long 
processing times (several hours) and, as a consequence, aggregation phenomena may occur 
between the droplets, producing microspheres with a larger poly-dispersity with respect to the 
droplets in the starting emulsion [54].  
Spray-drying is also used for biopolymer microsphere production because it is a 
relatively simple and of high throughput technology, but, cannot be used for almost all the 
PLGA co-polymer ratios because many of them are highly temperature sensitive biopolymers. 
As a consequence the production of PLGA submicro and microparticles with a controlled and 
narrow particle size in a robust and reproducible manner is still a challenge [55].  
 
1.6 About Supercritical fluids  
A supercritical fluid (SCF) is any substance at a temperature and pressure above its 
critical point. It can effuse through solids like a gas, and dissolve materials like a liquid. In 
addition, close to the critical point, small changes in pressure or temperature result in large 
changes in density, allowing many properties of a supercritical fluid to be "fine-tuned". 
Supercritical fluids are suitable as a substitute for organic solvents in a range of industrial and 
laboratory processes.  
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There is also reduced surface tension in a supercritical fluid, as well as, no liquid/gas 
phase boundary and by changing the pressure and temperature of the fluid, the properties can 
be tuned to be more liquid- or gas-like. One of the most important properties is the solubility 
of material in the fluid; it increases with density of the fluid (at constant temperature); 
whereas, at constant density, it increases with temperature. However, close to the critical 
point, the density can drop sharply with a slight increase in temperature. Therefore, close to 
the critical temperature, solubility often drops with increasing temperature, then rises again 
[56]. The continuous adjustable solvent power/selectivity obtainable by varying pressure and 
temperature of a supercritical fluid can be used in different sections of the plant to obtain 
different extraction/separation performances. The diffusivity of supercritical fluids is similar 
to that of gases; it is about two orders of magnitude larger than that of liquid solvents.  
Carbon dioxide and water are the most commonly used supercritical fluids, nowadays 
used in several industrial processes, such as, coffee decaffeination and power generation, 
respectively. Particularly, carbon dioxide (SC-CO2) behaves like a lipophilic solvent, it is not 
toxic, non flammable, it does not produce pollution (it is not produced during the process and 
is used many times before discharge), it is very cheap and its critical parameters of pressure 
and temperature are readily accessible on the industrial scale. Figures 1.1 show projections of 
a carbon dioxide phase diagram. In the pressure-temperature phase diagram the boiling 
separates the gas and liquid region and ends in the critical point, where the liquid and gas 
phases disappear to become a single supercritical phase. At well below the critical 
temperature (280K for CO2), as the pressure increases, the gas compresses and eventually (at 
just over 40 bar) condenses into a much denser liquid, resulting in the discontinuity in the line 
(vertical dotted line). The system consists of 2 phases in equilibrium, a dense liquid and a low 
density gas. As the critical temperature is approached (300K for CO2), the density of the gas 
at equilibrium becomes denser and that of the liquid lower. At the critical point, (304.1 K and 
73.8 bar for CO2), there is no difference in density and the two phases become one fluid 
phase. Thus, above the critical temperature a gas cannot be liquefied by pressure. At slightly 
above the critical temperature (310K for CO2), narrow to the critical pressure, the line is 
almost vertical; it means that a small increase in pressure causes a large increase in the density 
of the supercritical phase. Many other physical properties also show large gradients with 
pressure near the critical point, e.g. viscosity, the relative permittivity and the solvent 
strength, which are all closely related to the density. 
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Figure 1.1a-b. (a) Carbon dioxide pressure-temperature phase diagram; (b) Images of supercritical 
carbon dioxide in the biphasic region (1) in the supercritical passage near the critical point (2-4). 
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1.7 Supercritical fluids technologies for scaffolds production 
The first use of SCF for temporary scaffolds production has been tested into the SC gas-
foaming technique (also described previously). The process is solventless and very efficient in 
producing the porous biopolymeric structure, but generally closed-cells structures are 
generated; therefore, a CO2 foaming plus solid porogen technique (i.e., foaming/particulate 
leaching technique) to overcome the limited cell connectivity of the scaffolds was adopted 
[57]. For example, Mathieu et al. [58]. have shown that the morphology of the foams can be 
controlled to mimic the bone structure. Bone from different sites around the body is 
anisotropic, both morphologically and mechanically. They found that similar anisotropic 
structures can be formed by controlling the depressurization rate of the foamed PLLA and the 
density of the gas: rapid depressurization locked in large numbers of spherical cells, whereas a 
slower depressurization enabled cell elongation. However, in the foaming process, the rough 
nano-porous internal structure that should mime the natural extra-cellular matrix necessary to 
obtain a good cell adhesion and growth is completely missing. 
Another technology proposed for scaffold production is the supercritical assisted phase 
inversion. Compared with the traditional phase inversion method the main advantage is that 
SC-CO2 can dry the polymer membrane rapidly and totally avoiding structure due to the 
absence of a liquid-vapour interface. Moreover, the dry polymeric structures can be obtained 
without additional post-treatment because there are no traces of organic solvents. The 
substitution of SCF to the traditional liquid non-solvent phase allows for the tuning of 
antisolvent strength (density) by means of pressure introducing an additional variable to 
influence the demixing process and the membrane morphology. For example, Tsivintzelis et 
al., [59] reported that it is possible to control the scaffolds morphology changing the operative 
conditions; indeed, the average pore size decreased with the increase of CO2 density either by 
increasing the pressure or by decreasing the temperature, whereas the average pore diameter 
decreased with the increase of the initial polymer concentration. All the nano-composite 
materials exhibited more uniform cellular structures with large pores than the pure polymer. 
However, the structures obtained using this approach suffers various limitations. Indeed, it is 
very difficult to obtain complex 3D structures and rough nanofibrous internal structure that 
should mime the natural extra-cellular matrix necessary to obtain a good cell adhesion and 
growth (smooth cell walls are usually obtained). 
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To fulfil the necessity of producing interconnected microcells and a nanometric 
substructure, a new supercritical fluid assisted technique for the formation of 3D PLLA 
scaffolds has been proposed [60]. It consists of three sub-processes: the formation of a 
polymeric gel loaded with a solid porogen, the drying of the gel using SC-CO2 , the washing 
with water to eliminate the porogen. When PLLA gel drying is performed by supercritical 
CO2, the supercritical mixture formed during the process (solvent plus CO2) has no surface 
tension and can be easily eliminated in a single step by the continuous flow of SC-CO2 in the 
drying vessel. The major problem in gel drying is the possibility of gel collapse. In this case, 
the absence of surface tension avoids this problem preserving the nanoporous structure. On 
the other side, large interconnected cavities necessary to mime the tissue to be replaced are 
completely missing. To overcome this limitation, the authors proposed a hybridization of the 
supercritical drying process with the particulate leaching. These scaffolds were successfully 
tested for human mesenchimal cells cultivation [61]. 
 
1.8 Supercritical fluids technologies for microcarriers production 
In the last ten years, different supercritical fluid technologies were tested to produce 
PLGA nano and microdevices such as, the Rapid Expansion of Supercritical Solutions 
(RESS) and the Supercritical AntiSolvent (SAS) [62]. In RESS technology, SC-CO2 
solubilizes the compound to be treated and produces microparticles by a rapid decompression 
of the supercritical solution and the subsequent sovrasaturation of the solubilized biopolymer. 
SAS technique uses SC-CO2 as anti-solvent agent to induce the biopolymer precipitation from 
its liquid solution. The main problem reported for RESS technology is the very low solubility 
of almost all PLGA co-polymers in SC-CO2 that will prevent affordable process yields or will 
require the use of co-solvent [63]. On the other hand, the solubility of SC-CO2 in the PLGA 
(even if very low) is again the main problem for SAS technology. Indeed, the SC-CO2 
solubility in PLGA microparticles caused their agglomeration in products with irregular 
shapes [64] or recovered with a low yield due to the strong tendency to form a film [65]. It is 
also worth of mention that PLGA is able to uptake CO2 by sorption, leading to a significant 
decrease in its glass transition temperature [66] that will advantage the formation of glued 
particles.  
The use of SC-CO2, for PLGA microparticles manufacturing, has also been proposed 
starting from emulsions containing PLGA in the dispersed oily phase. Particularly, SC-CO2 
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was proposed as extracting agent of the oily phase of oil-in water (o-w) emulsions to lead to 
solvent-free microparticles [67-68]. In details, the Supercritical Emulsion Extraction process 
(SEE) produces an aqueous suspension of PLGA microparticles using CO2 to extract the 
solvent of the oily phase of an oil-in-water emulsion. In the SEE process, the above 
mentioned PLGA microparticles aggregation phenomena, were not observed, due to the 
presence of the external water phase, immiscible with SC-CO2, which prevents their 
aggregation [69]. One of the major limitations of the SEE technology, also shared with 
traditional evaporation/extraction processes, is the fact that this process is intrinsically 
discontinuous. Indeed, a batch of emulsion can be treated for each run; therefore, from a 
biotechnological and regulatory point of view, there will be problems of batches 
reproducibility and low process yield, due to material lost on the walls of the precipitation 
vessel.  
As discussed above, PLGA microcarriers also attracted significant attention in recent 
years, as building blocks for sintered scaffold formation offering several benefits including 
control over morphology and physicochemical characteristics and versatility of encapsulated 
factors release kinetics. The properties of a scaffold, in turn, can be tailored by altering the 
microsphere design and fabrication method, e.g., to create gradient-based scaffolds. In lieu of 
conventional temperature-regulated or organic solvent-assisted scaffold fabrication, 
supercritical fluid (SCF) technology has offered an alternative method of melt processing of 
the polymers. Singh et al. [70] capitalizing on the plasticizing ability of CO2, described a 
novel microsphere-based scaffold fabrication technique which also allows the production of 
PLGA shape-specific scaffolds. The authors also demonstrated that the CO2 sintering 
technique is suitable for producing cell-containing, shape-specific matrices (patches and 
scaffolds) under relatively mild conditions via a single-step sintering of PLGA microspheres 
in the presence of cells, with high cell viability. 
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Aims of the thesis 
 
Regenerative medicine requires engineered temporary scaffold able to support and 
influence cell microenvironment during their growth and/or differentiation. Supercritical 
Fluid processes are promising technologies for bioactive microdevices production able to 
overcome many drawbacks presented by conventional methods. As a consequence the aims of 
this work are: 
 to develop and optimize an innovative Supercritical Emulsion Extraction (SEE) 
technique, operating in Continuous mode to produce PLGA bioactive microcarriers to 
be loaded into 3D scaffold for tissue engineering applications. The innovative SEE-C 
process arrangement will be obtained by using a high pressure packed column 
operating in counter-current in which mass transfer between the liquid and the gaseous 
phases is improved by the internal packing elements. The process operating 
parameters such as, pressure, temperature and phase compositions (thermodynamic 
optimization) and flow rate ratios (fluidodynamic optimization) will be also study and 
optimized in order to increase encapsulation efficiency and reduce batch-to batch 
repeatability drawbacks.  
 to produce different PLGA microcarriers and characterize their morphology, particle 
size and distribution and active compounds loading and their release profiles in 
different media. Among the active compounds proteins and growth factors (GF) will 
be also considered.  
 to test the activity of PLGA microcarriers for the “in situ” sustained delivery of 
bioactive molecules in cell cultivation medium and/or when embedded in more 
complex 3D scaffold. Bioactive scaffold loaded with PLGA microcarriers will be also 
tested on dynamic cultivation by using a bioreactor for cell differentiation in 
dependence of active substance loading and release. Steam cells differentiation will be 
considered for this part of the study and ECM component productions and their 
evolution at different time points will be also evaluated. 
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Chapter 2. Continuous Supercritical 
Emulsions Extraction: a new technology for 
PLGA microcarriers production  
 
2.1 Introduction 
Poly-lactic-co-glycolic acid (PLGA) is a well-know biodegradable polymer that has 
received a great interest for the development of micro-particulate based formulations. PLGA 
microparticles can be administered by in-situ injection, achieving a precise and localized drug 
delivery which is more effective in many cases such as, for chemioterapy, hormone therapy, 
DNA/protein or vaccine delivery, as discussed in details in the previous chapter. Moreover, 
PLGA microparticles with a specific size and distribution have also been proposed for the use 
in tissue engineering as building blocks of implantable 3D scaffolds because of the several 
benefits offered such as, versatility of the release kinetics of encapsulated growth factors for 
cellular function orienting and directing [71]. PLGA microparticles can be also used as 
biodegradable support for cell culture and/or cell administration in the so-called “injectable 
scaffolds” which may affect stem cells lineage restriction and, after polymer degradation, 
allow a complete integration of the grafted cells in the host tissue [72-74]. 
The aim of this part of the work is to use the new SEE process operating in Continuous 
mode (SEE-C) to investigate the production of PLGA microparticles with an engineered size 
and distribution. This innovative process arrangement is obtained by using a high pressure 
packed column operating in countercurrent in which mass transfer between the liquid and the 
gaseous phases is improved by the internal packing elements. The analysis of the SEE-C 
operating parameters such as, pressure, temperature, phase composition and flow rate ratios is 
also proposed together with the comparison of SEE-C process performance with the ones of 
the corresponding batch operating mode processes (supercritical and conventional 
evaporation) in terms of process yield and PLGA particle size distribution. A detailed 
characterization of microparticles in terms of size distribution, morphology and solid state is 
proposed and a study on the PLGA microparticles degradation is performed to monitor any 
morphological difference between these biodegradable devices produced by SEE-C and the 
ones obtainable by conventional evaporation technology. 
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2.2 Experimental Methods 
2.2.1 Materials, Emulsion Preparation & Methods 
CO2 (99.9%, SON, Naples, Italy), polyvinyl alcohol (PVA, Mol wt: 30000–55000, 
Aldrich Chemical Co.), ethyl acetate (EA, purity 99.9%, Aldrich Chemical Co., Milan, Italy) 
poly-(lactic/glycolic) acid (PLGA, 75:25 Mol wt; 60000-120000 Aldrich Chemical Co.) were 
used as received. To prepare single o-w emulsions (composition ratio 20:80 w/w), a known 
amount of polymer was dissolved into EA to form an organic solution. Then, the solution was 
added into a known amount of EA-saturated aqueous PVA solution (0.8% w/w in water) to 
form an emulsion using a high-speed stirrer (mod. L4RT, Silverson Machines Ltd., 
Waterside, Chesham Bucks, United Kingdom) operated at 2800 rpm for 3 min. The oily phase 
contained fixed PLGA amounts ranging from 5 to 10% w/w depending on the test performed. 
To prepare double w-o-w emulsions (composition ratio of 1:19:80 w/w/w), 1 mL of 
water/PVA solution (0.04% w/w in water) was added in EA/PLGA solution and sonicated for 
2 min (mod. VCX130, Vibra Cell, Sonics & Materials, Inc., Newtown, CT, USA). This 
primary emulsion was, then, added into a known amount of EA-saturated aqueous PVA 
solution to form the secondary emulsion. In this case, the oily phase contained fixed PLGA 
amounts ranging from 2.5 to 10% w/w depending on the test performed. 
2.2.2 SEE apparatus  
SEE-batch operation layout (SEE) apparatus consisted of a 0.25 dm
3
 cylindrical 
stainless steel extractor. SC-CO2 was delivered using a high pressure diaphragm pump 
(Milton Roy, model Milroyal B, Point Saint Pierre, France) and was bubbled into the 
extraction vessel at a constant flow rate (0.4 Kg/h), through a cylindrical stainless steel porous 
dispenser located at the bottom of the extractor. Temperature inside the extractor was 
controlled using an air-heated thermostated oven. A separator located downstream the 
extractor was used to recover the solvent of the oily phase; pressure in the separator was 
regulated by a backpressure valve. At the exit of the separator, a rotameter and a dry test 
meter were used to measure the CO2 flow rate and the total quantity of CO2 delivered, 
respectively. When the extraction process was complete, the microspheres suspension was 
removed from the bottom of the extraction vessel for further processing. A schematic 
representation of the SEE process layout is reported in Figure 2.1a. 
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2.2.3 SEE-C apparatus 
A schematic representation of the SEE-C process layout is reported in Figure 2.1b. The 
P&D description is reported in Figure 2.1c. The apparatus consists of a packed column with 
an internal diameter of 13 mm, in which carbon dioxide (C) is fed from the bottom of the 
column using a high-pressure diaphragm pump (SC_P, mod. Milroyal B, Milton Roy, Pont 
Saint-Pierre, France), and the emulsion (E) is delivered from the top of the column using a 
high pressure piston pump (L_P, mod. 305, Gilson, Villiers-le-Bel, France). The column is 
formed by three AISI 316 stainless steel cylindrical sections of 30 cm height, connected by 
four cross-unions and is packed with stainless steel packings 4 mm nominal size with 1889 
m
−1
 specific surface and 0.94 of voidage (0.16 inch Pro-Pak, Scientific Development 
Company, State College, PA, USA). The apparatus is thermally insulated by ceramic cloths 
and its temperature is controlled by six controllers (TC1-TC6, Gordon J/Series 93, Watlow, 
Milan, Italy) at different heights of the column. The extracted solvent is recovered in a 
separator (S) put downstream the top of the column in which the pressure is regulated by a 
backpressure valve (V5, 26-1700 Series, Tescom, Selmsdorf, Germany). A rotameter (R, 
mod. N5-2500, ASA, Sesto San Giovanni, Italy) at the exit of the separator measures the CO2 
flow rate delivered. The start-up of the extraction process begins delivering SC-CO2 from the 
bottom of the column until the operating pressure is reached. Then, the emulsion delivery is 
started at the top of the column and the two flow rates are set at fixed values. The 
microparticles suspension was collected at the bottom of the column, washed several times 
with distilled water and, then, recovered by membrane filtration. 
2.2.4 Morphology & Size Distributions  
The droplets contained in the emulsion were observed using an optical microscope 
(mod. BX 50 Olympus, Tokyo, Japan) equipped with a phase contrast condenser. A Field 
Emission-Scanning Electron Microscope (FE-SEM mod. LEO 1525, Carl Zeiss SMT AG, 
Oberkochen, Germany) was used to study the morphology of the PLGA microparticles. A 
sample was mounted on a carbon tab previously stuck to an aluminium stub. Samples were 
coated with gold (layer thickness 250Å) using a sputter coater (mod.108 A, Agar Scientific, 
Stansted, UK). Droplet size distribution (DSD) and particle size distribution (PSD) were 
measured by dynamic light scattering (DLS, Mastersizer S, Malvern Instruments Ltd., 
Worcherstershire, UK). The Mastersizer S software uses Mie theory to produce an optimal 
analysis of the light energy distribution and to obtain the size distribution of the particles. 
 33 
Analyses were performed immediately after the preparation of the emulsion and of the 
microparticles suspension, using several milligrams of each sample. The volumetric particle 
size distributions curves were proposed in a cumulative form. 
2.2.5 Solid state characterization 
Diffraction patterns were obtained using an X-ray diffractometer (mod. D8 Discover, 
Bruker AXS, Inc., Madison, USA) with a Cu sealed tube source. Samples were placed in the 
holder and flattened with a glass slide to assure a good surface texture. The measuring 
conditions were as follows: Ni-filtered CuK radiation, λ = 1.54 Å, 2 angle ranging between 
5° and 70° with a scan rate of 3 s/step and a step size of 0.2°. Thermograms were obtained 
using a differential scanning calorimeter (DSC mod. TC11, Mettler Toledo, Inc., Columbus, 
USA). Fusion temperature and enthalpy were calibrated with an indium standard (melting 
point 156.6°C). The samples (5 mg) were accurately weighed, crimped in an aluminium pan 
and heated from to 25 to 300°C at 10°C/min, under a nitrogen purge of 50 mL/min. X-ray and 
DSC analyses were performed in three replicates for each batch of material.  
2.2.6 Microparticles degradation study 
100 mg of PLGA microparticles were suspended in 20 mL of water, agitated at 50 rpm 
at 37°C. 10 l of suspension were sampled every 4 days, dried and mounted on an aluminium 
stub for the morphological analysis by FE-SEM. The suspension pH was measured by a 
pHmeter (mod. pH 210, HANNA instruments, Italia). 
2.2.7 Solvent residue analysis 
The EA content in the recovered suspension of PLGA microparticles was analyzed to 
determine the efficiency of solvent removal from the emulsion. The EA residue was measured 
using a head space sampler (mod. 50 Scan, Hewlett & Packard, Palo Alto, CA, USA) coupled 
to a gas chromatograph interfaced with a flame ionization detector (GC-FID, mod. 6890 
Agilent Series, Agilent Technologies Inc., Wilmington, DE). EA was separated using a fused-
silica capillary column 30 m length, 0.25 mm internal diameter, 0.25 m film thickness (mod. 
DB-1, J&W, Folsom, CA, USA). GC conditions were: oven temperature at 40°C for 8 min. 
The injector was maintained at 180°C (split mode, ratio 1:1) and Helium was used as the 
carrier gas (7 mL/min). Head space conditions were: equilibration time 60 min at 100 °C, 
pressurization time 2 min, loop fill time 1 min. Head space samples were prepared in 10 mL 
vials filled with 3 mL of suspension. Analyses were performed on each sample in three 
replicates.  
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SEE 
(a) 
 
SEE-CM 
(b) 
 
 
Figure 2.1a-b. Schematic representation of SEE and SEE-C processes layouts. SEE is an intrinsically 
batch process (a); SEE-C allows a continuous emulsion processing by using a countercurrent packed 
tower (b).  
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Figure 2.1c. SEE-C apparatus P&I description. C, CO2 supply; E, emulsion supply; PG_1 and PG_2, 
pressure gauges; SC_P, diaphragm pump used for high pressure SC-CO2; L_P, piston pump used for the 
emulsion; TC1-TC8, thermocouples/controllers; S, separator; R, rotameter; E_1 and E_2, heat 
exchangers; V1-V8, valves.  
 
2.2.8  Correlations for flooding point calculation 
Flooding point can be calculated using standard procedures based on the use of graphs 
reported in the literature. The first is the “Generalized Pressure Drop Correlation” (GPDC) 
[75], that describes the balance between the up-flowing gas momentum force and the 
gravitational forces acting on the liquid droplets; it is a function of the physical properties of 
the gas and of the liquid stream; therefore, mass flow rates, gas and liquid densities, viscosity 
of the liquid, as well as a packing factor must be known. The other two correlations tested are 
the “Brunner correlation”, that is the GPDC correlation modified by Brunner for towers 
operating with supercritical CO2 [76] and the “Random packing correlation”(RPC) that is 
specific when random elements are loaded [77]. The correlation proposed by Brunner allows 
to calculate flooding points for packed columns with structured packings. Particularly, the gas 
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capacity factor on the ordinate is a measure of the gas velocity necessary to suspend a liquid 
droplet, and the flow parameter on the abscissa rates the kinetic energy of the liquid phase to 
the kinetic energy of the gaseous phase. The “Random packing correlation” depends on 
liquid and gas flow rates, surface area of packing per unit lower volume, fractional void 
volume of dry packing, liquid viscosity, local acceleration due to gravity, liquid and gas 
densities. This last correlation shows three separate curves: the intermediate curve can be used 
for random packings, the upper curve is used for stacked packings and the lower curve is for 
indicating an approximate lower limit when random packings are loaded. 
 
2.3 Results & Discussion 
2.3.1 SEE-C parameters: pressure & temperature 
The extraction pressure and temperature conditions of 80 bar and 38°C were chosen for 
processing emulsions with an oily phase content of about 20% w/w. These conditions were 
selected to assure the complete miscibility of EA in SC-CO2 [78-79]; whereas, at the same 
conditions, the solubility of water (the continuous phase) in CO2 is of 0.53∙10
-3
 (as molar 
fraction), so very low and it can be neglected [80-82]. A temperature of 38°C is also 
compatible with the glass transition temperature of PLGA (co-polymer ratio 75:25, see also 
materials section) that is located at about 40°C [83].  
Moreover, during the SEE continuous operation, a mass transfer between the two 
phases is activated, but, variations in the top and bottom product composition can be observed 
until steady state conditions have been obtained. As a consequence, another relevant process 
parameter, in the continuous operation, is the time required to obtain steady state composition 
in the column. So that, in some preliminary experiments, performed at the conditions 
described above and using an empty o-w emulsion (ratio 20:80), it was observed that after 30 
min, the solvent residue in the water recovered at the bottom of the column became almost 
constant and lower than 300 ppm. Following these indications, the SEE-C experiments were 
always performed after reaching the steady state conditions by using an empty emulsion and a 
solvent residue values lower than 300 ppm were measured in all PLGA suspensions recovered 
in the following part of the work.  
The use of packed towers is commonly not suggested for processes involving the 
presence of a solid phase; indeed, it should be expected that the solid precipitate from the 
 37 
liquid phase and cover the packing surface, producing a reduction of the mass transfer and, 
then, the blockage of the column. However, in the SEE-C, this event was not observed. There 
are two good conditions to explain why this phenomenon does not significantly interfere with 
the continuous solvent elimination process. As the dimensions of the microparticles produced 
(related to droplet diameters) are always in the micronic range, they will show the tendency to 
remain suspended in the falling liquid film inside the column (i.e., particles residence time in 
the column is expected to be shorter than their sedimentation time); moreover, the presence of 
the surfactant on the particle surfaces will allow their easy slipping on the packing surfaces. 
The presence of surfactant around the microparticles suspension is also useful for their 
recovery at the bottom of the column since it avoids any other particle collapsing or 
aggregation. Moreover, the Joule-Thomson effect that follows the CO2 lamination, induces a 
strong cooling effect on the microparticles suspension (2-4°C are normally reached), 
improving PLGA particles stability during their recovery.  
2.3.2 SEE-C parameter: evaluation of flooding  
In the classical interpretation of a liquid extraction process, mass transfer is 
concentrated at the interface between the two films formed by liquid and gas phase [84]. This 
schematization can be also applied to SEE-C process; therefore, mass transfer between the 
liquid and the dense gas can take place at the interface between the film of liquid moving 
downwards on the surface of the packing and the film of SC-CO2 moving upwards in the 
column. In a countercurrent packed column, efficient mass transfer conditions are reached 
when the liquid flowing down over the packing begins to be held in the void spaces between 
the packing; this is called the loading condition and the pressure drop in the column begins to 
increase. Further increases in gas or liquid velocity will produce further increases of the 
pressure drop, until the liquid completely fills the void spaces in the packing, hindering the 
gas flow; therefore, the liquid cannot flow down through the column and it is forced to flow 
up, together with the gas stream. This condition is referred as flooding and the column is no 
more operative. Given a packed column, for a fixed gas rate, there is a definite liquid rate 
above which the column will flood; similarly, at any given liquid rate, there is a definite gas 
rate above which the column gives flooding. Moreover, the flooding point depends on the 
density difference between the two phases involved, as well as, when emulsions are used in 
the column, by the foam generated from the surfactant that reduces the free area for gas flow.  
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The flooding experiments at different CO2 densities were performed on the apparatus 
previously described, using water as the liquid phase and supercritical carbon dioxide as the 
dense gas phase. For each experiment, gas flow rate and CO2 density (i.e. pressure and 
temperature conditions) were fixed; whereas, the liquid velocity was increased by small steps 
to measure the increase of the pressure drop, until the flooding point was reached. We first 
measured the limit in density difference between the liquid and gas phase that allows 
countercurrent operation; the results are reported in Figure 2.2 at fixed L/G ratios. For CO2 
densities lower than ~0.6 g/cm
3 
(below the dashed line), the gas to liquid (water) density 
difference allows the proper interaction of the two phases; for CO2 densities larger than ~0.6 
g/cm
3 
(above the dashed line), entrainment of the liquid phase increases rapidly until flooding 
occurs; small changes in the flow rates near the limit conditions lead to an unstable process. A 
similar value of the density difference was also found by Brunner and co-workers that, 
operating a continuous supercritical fractionation process of fish oil ethyl esters, found that 
the operating point at 0.603 g/cm
3
 was close to the flooding point [85]. Flooding velocities as 
a function of the liquid/gas ratio for different densities are reported in Figure 2.3: at constant 
L/G ratio, the flooding velocity decreases with the increase of CO2 density.  
For comparison purposes, CO2 flow rates at flooding conditions were also calculated 
using the various correlations discussed in the methods section; the obtained values are listed 
in Tables 2.1 and 2.2 at different L/G ratios and at different densities, respectively. The 
flooding values experimentally measured are also reported. Looking at the data, SC-CO2 
flooding flow rate (Gf) decreases with the increase of L/G for all literature correlations and the 
same trend has been found for the experimental values produced in this work. But, the Gf 
values calculated from the literature are from about 2.5 to 4 times larger than our 
experimental data; moreover, their variation with L/G is also less pronounced. Possible 
explanations for these differences are that literature correlations have been produced for 
processes using gases at ordinary pressure conditions, i.e. near the atmospheric pressure, 
where gas densities are very small compared to those of supercritical CO2. The only exception 
is Brunner’s correlation that has been developed for SC-CO2; however, in that case, structured 
packings have been used that allow a larger void section through the column, to which 
correspond larger spaces for gas to flow up, with reduced interactions with the liquid. In our 
apparatus, instead, very small random packings are used.  
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When L/G is varied between 0.1 and 0.4, the corresponding limits for liquid flow rates 
are indicated in Table 2.3. Using the results discussed until now, efficient separations in the 
column are obtained with a flow rate of 1.4 Kg/h of CO2 that corresponds to the 50% of the 
flooding experimental value, when operating at 80 bar, 38°C with a L/G ratio of 0.1.  
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Figure 2.2.  Effect of the gas density upon flooding for different L/G ratios (dashed line: boundary line 
between proper process conditions and flooding).    
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Figure 2.3.  Flooding velocities as a function of the liquid/gas ratio (L/G) for different CO2 densities: (■) P 
= 80 bar, T = 38°C, ρ = 0.31 g/cm3 and (●) P = 100 bar, T = 44°C, ρ = 0.52 g/cm3). 
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Table 2.1. Evaluation of the Gf conditions varying the L/G ratio between 0.1 and 0.4 at fixed T = 38°C and 
P = 80 bar (ρ = 0.31 g/cm3) using the correlations previously discussed. 
L/G 
Gf [Kg/h] 
GPDC Brunner RPC This work 
0.1 10.25 11.26 7.50 2.82 
0.2 8.68 9.38 6.64 1.40 
0.4 7.09 7.51 5.21 1.00 
 
Table 2.2. Evaluation of the flooding conditions varying the density at fixed L/G = 0.1, using the 
correlations previously discussed. CO2 density of 0.31 g/cm
3
 correspond to 80 bar and 38°C; 0.52 g/cm
3
 to 
100 bar and 44°C.  
CO2 density 
Gf [Kg/h] 
(g/cm³) 
GPDC Brunner RPC This work 
0.31 10.25 11.26 7.50 2.82 
0.52 10.24 11.23 9.26 2.61 
 
Table 2.3. Liquid and SC-CO2 flow rates used at different values of L/G. 
L/G 
SC-CO2 flow rate liquid flow rate 
[Kg/h] [Kg/h] 
0.4 1.4 0.56 
0.2 1.4 0.28 
0.1 1.4 0.14 
 
2.3.3 Droplets & microparticles size and morphology  
It is known that the size of the particles is directly related to the emulsion droplet size 
and, therefore, depends on the emulsion formulation. Particularly, the increase of the oily 
solution viscosity, due to a higher polymer concentration in the solvent, can produce larger 
droplets when using the same dispersion shear force and surfactant concentration during the 
emulsion production [86]. Following this indication, SEE-CM experiments (in steady state 
conditions) were performed by processing 100 g of single (o-w) and/or double (w-o-w) 
emulsions in each run, varying the PLGA content in the oily phase from 5 to 10% w/w to 
obtain PLGA microparticles of increased mean size. All the distribution data of the droplets 
and of the microparticles produced are summarized in Table 2.4.  
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Optical Microscope images of two different emulsions (o-w single emulsion produced at 
PLGA concentration of 5% w/w and w-o-w double emulsion with a PLGA concentration of 
10% w/w in the oily phase) are reported in Figures 2.4a-b, respectively. From the images it is 
clear that the emulsions were stable with non-coalescing droplets. The produced PLGA 
microparticles were spherical and non-coalescing as illustrated in the SEM images reported in 
Figures 2.5a-b. These images pertain to particles obtained from single (left side) and double 
(right side) emulsions prepared with PLGA concentrations in the oily phase of 5 % w/w (see 
Figure 2.5a) and of 10% w/w (see Figure 2.5b). All the SEM images reported have been 
taken at the same amplification and it is clear that the increase of the mean particle size from 
1 to 3 m when PLGA concentrations in the oily phase were increased from 5 to 10% w/w. 
The PSD of the particles obtained from o-w emulsions containing 5% and 7.5% w/w of 
PLGA in the oily phase are also reported in a cumulative representation in Figure 2.6. The 
DSDs of the two emulsions processed by SEE-C are reported in the same figure, for 
comparison purposes. Droplets curves practically overlap, showing that the variation of 
PLGA concentration from 5 to 7.5% w/w in oily phase do not really influenced the droplets 
size that was similar. However, the PSD of the microparticles originated from the droplets 
containing 5% w/w of PLGA is sharper than the PSD of the microparticles from droplets 
containing 7.5% w/w of PLGA. This fact is due to the droplet shrinking factor (defined as the 
ratio between the particles and droplets mean sizes, SF = MSS/MSE) that also plays a relevant 
role in determining the final size of the microparticles. The droplets with a higher percentage 
of polymer have a lower possibility to shrink when the solvent is eliminated; therefore larger 
particles are produced [87]. Particularly, the obtained particles are about 60% and 33% 
smaller, respectively, than the original droplets.  
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Figure 2.4a-b. Optical Microscope images of two emulsions: (a) single o-w (20:80; composition: EA plus 
PLGA 10% w/w; external water with PVA 0.8% w/w) and (b) double w-o-w (1:19:80; composition: 
internal water plus PVA solution 0.04% w/w; oil EA plus PLGA 10% w/w; external water with PVA 0.8% 
w/w.  
 
  
 
(a) 
 
 
Single 
 PLGA 5% w/w 
 
Mean Size 2.4 m (SD 1.0 m)  
 
(b) 
 
 
Double  
PLGA 10% w/w 
 
Mean Size 3.5 m (SD 1.8 m)  
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Table 2.4. Dynamic laser scattering size distribution data of droplets (DSD) and of microparticles (PSD) 
produced at different PLGA concentrations in the oily phase using SEE-C of single (o-w) and double (w-o-
w) emulsions. Legend: MS = mean size; SD = standard deviation; CV = coefficient of variation; SF = 
shrinking factor. 
 
Droplet Size Distributions (DSDs) Particles Size Distributions (PSDs) 
 
o/w  w/o/w o/w  w/o/w  
PLGA 
% w/w  
5 7.5 10 10 5 7.5 10 10 
MS (μm) 2.4 2.6 4.1 4.1 1.0 1.8 3.3 3.5 
SD (μm) 1.0 1.2 2.1 2.1 0.4 0.8 1.6 1.8 
CV(SD/MS) (%) 41 46 51 51 40 44 48 51 
SF(MDS/MDE) -- -- 
 
-- 0.41 0.67 0.80 0.85 
D10 (μm) 1.1 1.2 1.5 1.5 0.4 0.7 1.1 1.2 
D50 (μm) 1.8 1.8 3.0 3.1 0.7 1.3 2.3 2.6 
D90 (μm) 2.7 2.7 4.9 5.1 1.2 2.1 3.8 4.6 
 
DSDs of the emulsion containing 10% w/w of PLGA in the oily phase and PSDs of the 
related microparticles were also studied using single (o-w) and double (w-o-w) emulsions and 
the related size distribution curves are reported in the Figure 2.7. Double emulsions are more 
difficult to be processed by conventional solvent evaporation, since the emulsion is less stable 
and the produced microparticles are expected to be porous due to the entrapped internal water 
phase. Coalescence phenomena are frequent, as well as, the formation of concave particles 
due to the loss of the water internal phase and the formation of collapsed empty particles. 
PLGA concentration of 10% w/w in the oily phase produced droplets with almost the same 
distribution in the case of single and double emulsions. The PSDs cumulative curve of the 
microparticles generated from single emulsion showed a larger shift from the DSDs related 
curve, indicating a larger droplet shrinking (the gap between PSD/DSD at D50 values is 0.74 
m); whereas, when a double emulsion was processed, the size distribution curve of the 
generated particles showed a smaller shift (gap between PSD/DSD at D50 values is 0.49 m).  
The coefficient of variation (CV), defined as the ratio between standard deviation (SD) 
and mean size (MS), were evaluated for both droplet and particle distributions and its values 
are also reported in Table 2.4. The CV of the particle size distributions obtained by SEE-CM 
were in the range of 40-50 % and always lower or, at least, the same of the ones of the 
original emulsions, confirming the fine reproduction of the size distribution from droplets to 
particles of the supercritical continuous process.  
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Figure 2.5a-b. SEM images of PLGA microparticles obtained by SEE-C by processing both single and 
double emulsions containing PLGA in concentration of (a) 5% w/w and (b) 10% w/w; Operating 
conditions: 80 bar and 38°C, L/G ratio 0.1.  
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Figure 2.6. PSDs of PLGA particles produced from single (o-w) emulsions containing 5% and 7.5% w/w 
of PLGA in the oily phase. The DSDs of the two emulsions processed by SEE-C are also reported (dashed 
curves), for comparison.  
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Figure 2.7. PSDs of PLGA particles produced from single and double emulsions containing 10% w/w of 
PLGA in the oily phase. The DSDs of the two emulsions processed by SEE-C are also reported (dashed 
curves), for comparison. The gap between PSD/DSD at D50 values for single emulsion is 0.74 m); the gap 
between PSD/DSD at D50 values for double emulsion is 0.49 m). 
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2.3.4 Comparison between SEE, SEE-C and evaporation 
A comparison between the product obtained by SEE, SEE-C and conventional solvent 
evaporation process (SE) was performed using w-o-w emulsions that were processed using the 
three different technologies/process layouts. Mean sizes and distributions of PLGA 
microparticles obtained by SEE-C, SEE and by conventional solvent evaporation (SE) are 
reported in Table 2.5. In the same table the DSDs of the treated emulsions are also reported, 
for comparison purposes. Table 2.5 data confirmed that the SEE-C allows the recovery of 
particles with an MSs and SDs slightly smaller than the ones produced by the SEE and 
smaller than the ones produced by the SE. The reason should be in the very short processing 
time of all the emulsions treated by SEE-C. Indeed, considering as a reference time, the 
residence time of the liquid phase in the packed column, the continuous processing requires a 
residence time of the emulsion/suspension in the column of about 5 min; whereas, 30 min are 
the residence time of the emulsion/suspension treated by SEE and the 4-6 hours are necessary 
to perform the conventional SE (often also at higher temperatures). With respect to the SEE 
standard layout, the SEE-C offers other advantages such as, complete absence of aggregated 
particles and minimized lost of particle in the CO2 gas stream during the depressurization 
steps. Indeed, SEE usually shows a recovery percentage (defined as: PLGA charged in 
emulsion/PLGA recovered after the processing *100) variable from 40 to 60%; whereas, a 
recovering percentage of about 90% was measured in SEE-C.  
 
Table 2.5. Dynamic laser scattering size distribution data of droplets contained in double w-o-w emulsions 
and related PLGA microparticles size distribution produced using standard SEE layout, SEE-C and 
solvent evaporation process (SE). Legend: MS = mean size; SD = standard deviation; CV = coefficient of 
variation.  
 
Droplets 
m 
Microspheres 
m 
 
SEE SEE-CM SE 
MS (μm) 1.0 2.0 4.8 1.1 2.3 4.6 1.0 1.9 4.2 1.5 2.0 4.6 
SD (μm) 0.5 0.8 2.4 0.4 1.0 2.1 0.5 0.8 2.1 0.8 1.0 2.4 
CV (%) 50 40 50 36 43 46 50 42 50 53 50 52 
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2.3.5 Microparticles solid state and degradation  
Thermal analyses (DSC) were performed on microparticles obtained by SEE-C and on 
raw PLGA, for comparison purpose. The obtained thermograms are reported in Figure 2.8. 
PLGA shows a glass transition between 39 and 45°C (onset 39.98°C; endset 45.32°C) and the 
decomposition that occurs at above 300°C. The produced microparticles show the same glass 
transition and degradation event of the unprocessed polymer. X-ray analyses were also 
performed on the untreated polymer and on PLGA microparticles to have information about 
the solid state of the produced materials. The X-ray patterns are reported in Figure 2.9; they 
indicate that both unprocessed polymer and microparticles are amorphous, confirming the fast 
polymer precipitation inside the droplets during the microparticle formation by SEE-CM.  
2.3.6 Proposed process mechanism 
Precipitation of PLGA inside the droplets is induced by SC-CO2 extraction of the 
organic solvent of the oily dispersed phase. Although the detailed behavior of this process has 
not yet been defined, a possible mechanism can be described as follows; when emulsion and 
SC-CO2 come in contact, the mass transfer of the organic solvent proceeds by two parallel 
pathways: (A) the diffusion of the organic solvent into water followed by extraction of the 
solvent from the aqueous phase to SC-CO2; (B) the direct extraction upon contact between 
SC-CO2 and the organic phase inside the droplet (see Figure 2.10). The path (A) is the only 
one used to describe the conventional solvent evaporation because, in that case, the amount of 
solvent evaporated at the liquid air interface is compensated by the solvent diffusing into the 
continuous phase from the droplet [88]. This path can be justified also in the SEE-C process 
by the fact that a thermodynamic equilibrium occurs into the solvent-rich and aqueous-rich 
phases. Moreover, at the operating conditions selected, very large solubility of the oily phase 
is assured in SC-CO2; therefore, it may extract the solvent of the dispersed oily phase from 
the external water phase of the emulsion causing the subsequent diffusion of the solvent from 
the droplets to the continuous phase, to restore the thermodynamic equilibrium. This 
phenomenon may prevail, for example, in the case of EA because its solubility in water is 
particularly great (8.7% w/w at ambient conditions) [89].  
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Figure 2.8. DSC traces of unprocessed and PLGA microparticles produced by SEE-C. The polymer glass 
transition did not change after SEE-C processing. 
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Figure 2.9. X-ray profiles of unprocessed and PLGA microparticles produced by SEE-C. The polymer is 
clearly amorphous in both case. 
 
However, the co-existence of the path (B) in the SEE-C process should be confirmed by 
the process of water in oil emulsion reactions assisted by SC-CO2 for the production of metal 
oxides [90-91]. In that case, the CO2 was used not only as extracting agent of the organic 
external phase, but also, as a reagent that, reacting with the solute in the internal water phase, 
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forms metal oxides nanoparticles. In this particular application, the SC-CO2 diffusion into the 
droplet is necessary for the reaction evolution and the results reported in the literature, 
indicated a very a fast reaction rate after SC-CO2 diffusion into the droplets, through the 
surfactant shell.  
Mattea et al., [92] also observed the behaviour of a dichloromethane drop (covered by 
surfactant) in water after its contact with SC-CO2 at a given pressure, temperature and CO2 
molar fraction and reported possible swelling of the drops, after SC-CO2 diffusion in it (that 
may suggest the direct extraction of the solvent), suddenly overcame by a rapidly drop 
shrinking, probably due to the dichloromethane diffusion out of the drop into the external 
water phase (that may also suggest the indirect solvent extraction). Both mass transfer paths, 
namely “direct solvent extraction” and “indirect solvent extraction” from the external phase, 
may concur in generating the polymer supersaturation inside the droplet and its fast 
precipitation. However an hypothesis about the possible prevailing mechanism in the SEE-C 
process cannot be attempted at the moment due to lack of experimental data in the literature.  
 
 
Figure 2.10. Schematic representation of the possible mass transfer pathways of the oily phase during the 
SEE-C process. Two parallel pathways: (A) diffusion of the organic solvent into water followed by 
subsequent supercritical extraction of the solvent from the aqueous phase; (B) direct supercritical 
extraction upon contact between SC-CO2 and the organic phase into the droplet. 
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PLGA is well known for its bulk erosion properties [93]. In order to study the 
degradation of the microparticles produced by the supercritical process, two different batches 
of particles produced using single and double emulsions (with a fixed MS of 3 m, ±  0.75 
m) were suspended in distilled water at 37°C with an agitation of 50 rpm. The PLGA 
particles degradation starts in the first 48 hours, as indicated by the pH lowering of the 
suspension that decreased from 6.8 to 4.5. From each suspension, 10 l were sampled every 7 
days, dried and prepared for the morphological analysis by FE-SEM.  
The microparticles produced by single emulsion showed a complete erosion in 60 days 
The microparticles surface modification after 14 and 35 days are reported in Figures 2.11 (a-
b_left side). A smooth surface is still present on the particles sampled after 14 days of 
degradation. The progressive erosion starts to be evident after 35 days, when the microdevices 
became nanoporous.  
The microparticles produced by double emulsion showed a complete erosion in 50 days. 
Their surface morphologies after 14 and 35 days are also reported in Figures 2.11 (a-b_right 
side). A smooth surface can be still observed after 14 days of residence in distilled water 
(Figure 2.11a_right side); whereas, the circular structures observed on the microparticles 
surface should due to the polymer precipitation on the internal water phase of the double 
emulsion. Nanoporous and near-collapsed particles can be observed after 35 days, indicating 
the polymer bulk depolimerization (Figure 2.11b_right side).  
The overall period between 50-60 days, required for PLGA microparticles complete 
degradation in water coupled with a maximum pH lowering of the suspension to a values 
between 4.5 and 3.8 is in agreement with the literature data [94], which suggested a 
degradation time of 60 days for similar PLGA composition and particle sizes obtained by 
conventional solvent evaporation.  
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single o-w emulsion 
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Figure 2.11a-b. SEM images (Mag = 50.00 K X) related to a morphological study of PLGA microparticles 
degradation in water after 14 (a) and 34 days (b), respectively. The particles have a diameter of almost 3 
m and were produced by SEE-CM using a single (left side) and double w-o-w emulsions (right side).  
 
2.4. Others results on PLGA microcarriers charged with bioactive 
substances  
SEE-C technology was used to produce PLGA microdevices charged with several 
active principles, such as vancomicyn hydrochloride (VH, a glycopeptide antibiotic) and 
hydrocortisone acetate (HA, a corticosteroid) [95]. Different emulsions were tested to 
optimize the VH loading at 5% w/w (theoretical drug loading) into PLGA microspheres that 
showed MSs of 1.5 m (± 0.3 m). An example of SEM images of the PLGA/VH 
microspheres obtained is reported in Figure 2.12a; whereas, the related distribution curve is 
reported in Figure 2.12b; the emulsion DSD from which they are generated are also reported 
for comparison purpose in the same Figure, as dashed line.  
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Optical microscope (OM) image of double w-o-w emulsion (1:19:80 composition) 
containing PLGA in concentration of 10% w/w in the oily phase (HA loading is 9% w/w of 
PLGA) is reported in Figure 2.13a; the droplets produced were non-coalescing and exhibited 
a MS of 3.4 µm (± 0.8 µm). The PLGA microspheres produced are illustrated in the SEM 
image reported in Figure 2.13b; they were spherical and showed a MS of 3.1 µm (± 0.7 µm). 
Drug encapsulation percentages of 87% for VH and of 85% for HA, respectively, were 
measured [96]. 
From an o-w emulsion obtained with acetone and aqueous glycerol, SEE-C process was 
also tested for the production of PLGA microspheres charged with retinyl acetate (RA) and β-
carotene (CA). Microdevices with a MS of 6.5 µm (± 1.7 µm) were obtained with a good 
encapsulation efficiency of 70% for RA and 60% for CA, respectively. Examples of two 
emulsions are illustrated in the OM images reported in Figure 2.14a-b; whereas, SEM images 
of the obtained PAMs are reported in Figure 2.15a-b, respectively [97]. 
 
Figure 2.12a-b. SEM image of the PLGA/VH microspheres obtained by SEE from w-o-w emulsion. Mean 
Size: 1.5 m (SD ± 0.3 m), Variation Coefficient: 40% (a). Particle Size Distribution (PSD) curve of 
PLGA/VH microspheres obtained by SC-CO2 extraction (continuous line) and Droplets Size Distribution 
(DSD) curve of the droplets in the emulsion before SC extraction (dashed line) (b). 
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(a) (b) 
Figure 2.13a-b. Optical Microscope image of a double w-o-w emulsion (1:19:80 composition) containing 
PLGA in concentration of 10% w/w in the oily phase (HA is 9% w/w of PLGA) (a). SEM image of PLGA 
microspheres charged with HA (loading 6 % w/w) produced by SEE-C operating at 80 bar and 38°C, L/G 
ratio 0.1 (b).  
 
Figure 2.14a-b. (a): Emulsion o-w ratio 20/80, Oil: 45% PLGA with 3% RA; Water 80% glycerol, 20% 
water and 0.6% PVA. (b): Emulsion o-w ratio 20/80, Oil:45% PLGA and 6% β-carotene; Water 80% 
glycerol, 20% water and 0.6% PVA  
 
 
Figure 2.15a-b. SEM images of the PAMs produced (a): PLGA with 3% w/w of RA; PLGA with 6% β-
carotene (b).  
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2.5 Conclusions & Perspectives 
The successful upgrade of the batch SEE process to a continuous operating mode (SEE-
C) was illustrated. Greater product uniformity, higher throughput with smaller plant volumes 
and elimination of batch-to batch repeatability problems were the important advantages 
observed. The measurement of droplet-to-particle shrinking factors and the monitoring of 
microdevice degradation in a aqueous media demonstrated that the internal structure of the 
PLGA microdevices, is almost the same of the ones produced by conventional evaporating 
process; however, the faster solvent extraction will have a significant effect on the size 
distribution of the precipitated particles which are always smaller than (or at least reproduce 
exactly) the size of the originally droplets, avoiding the aggregation phenomena that occur 
during conventional slower processes. SEE-C allowed also higher encapsulation efficiencies 
expecially when double emulsions were treated.  
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Chapter 3. PLGA microdevices by SEE for 
Retinoic acid sustained release: evaluation 
of the kinetics constants  
 
3.1 Introduction 
All trans-retinoic acids (atRA) show a high therapeutic potential in the treatment of 
several diseases and, recently, they have also been included in anti-cancer therapeutical 
schemes [98]. However, atRA are very labile at ambient conditions and their degradation is a 
typical radical reaction, catalyzed by light, transition metals or free radicals [99]. Due to their 
short half-life and hydrophobicity, retinoids parenteral administration is very difficult and to 
date no commercial formulations are available. Different formulations have been investigated 
to overcome retinoids fast metabolization and to achieve their locally sustained release: 
encapsulation into injectable microspheres [100], emulsions [101], nanodisks [102], solid 
lipid nanoparticles (SLNs) [103] and nanoparticles [104]. Retinoids encapsulation in poly-
lactic-co-glycolic acid (PLGA) microparticles could be interesting for drug controlled release 
and/or targeting after local administration [105-106] and/or for tissue engineering application 
[107]. Emulsion evaporation with methylene chloride produced PLGA particles ranging from 
10 to 90 µm, with a maximum atRA loading efficiency of 59% in correspondence to a drug 
content of 2.3% w/w. It is also worth of mention that dichloromethane is still the most widely 
used oily phase solvent thanks to its high volatility; however, due to its carcinogenic nature, 
several efforts were made to replace it with ethyl acetate [108]. An atRA encapsulation 
efficiency of 47% was also reported for PLGA microspheres produced using chloroform 
[109]. Controlled release of retinol from silica particles was also reported by solvent 
evaporation of double oil-water-oil emulsions. In this case, the highest encapsulation 
efficiency was of 30% [110]. Recently, some authors reported the production of PLGA 
microspheres containing vitamin B12 prepared by emulsion extraction using an innovative 
emulsion composition formed by acetone (as the solvent for the oily phase) and aqueous 
glycerol. Acetone was then “extracted” with water [111]. 
The aim of this part of the study is to produce PLGA microparticles with high retinyl 
acetate (RA) encapsulation efficiency by using less toxic solvents (acetone & aqueous 
glycerol) applying Supercritical Emulsion Extraction technology (SEE). This technology will 
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be tested both in batch (SEE-B) and in continuous (SEE-C) operating layouts. The 
microdevices produced by SEE will be also compared with the ones obtainable by 
conventional liquid-liquid extraction (LEE) process. Detailed characterization of the 
microspheres will be also proposed, comparing the morphologies, size distributions and 
physico-chemical properties (solid state, solvent residue) of the different products obtained. 
Different RA loading and corresponding release profiles will be also evaluated in modified 
media (n-propanol/water) and kinetic constants will be calculated by fitting the experimental 
data with a mathematical model that takes into account either diffusion and degradation 
contributions. 
3.2 Experimental Methods 
3.2.1 Materials 
CO2 (99.9%, SON, Naples, Italy), polyvinyl alcohol (PVA, MW: 30,000–55,000, 
Aldrich Chemical Co.), acetone (AC, purity 99.9%, Aldrich Chemical Co.), glycerol (GLY, 
purity 99%, Aldrich Chemical Co.) retinyl acetate (RA, Aldrich Chemical Co.), poly(lactic-
co-glycolic) acid (PLGA, 75:25 MW: 20000, Resomer RG 752S, Boehringer) were used as 
received.  
3.2.2 Emulsions formulation & Liquid Emulsion Extraction (LEE) 
Emulsions with different o-w ratio of 20:80 and 10:90, respectively, were prepared. Oily 
phase was prepared dissolving fixed amount of the polymer (45% or 55% w/w of the oily 
phase) and drug (3 or 6 or 10 % w/w of the polymer) into acetone. Water phase was prepared 
dissolving PVA (0.6% w/w of the water phase) into aqueous glycerol solution (80:20 
glycerol/water). The oily phase was added into the water phase using a high-speed stirrer 
(mod. L4RT, Silverson Machines Ltd., Waterside, Chesham Bucks, UK) at 4000 rpm for 3 
min. 20 g of emulsion was charged in a beaker and the solvent was extracted adding dropwise 
60 g of aqueous-glycerol (ratio 50:50 water/glycerol), the resulting solution was stirred for 80 
min at 400 rpm; subsequently, 60 g of pure water were added dropwise and the extraction was 
performed at the same stirring conditions for other 100 min. 
3.2.3 SEE: apparatuses & microdevices characterization 
Schematic representation of the two SEE process layouts (batch and continuous 
operating mode) and detailed descriptions of the morphology and size evaluations of the 
produced microspheres were already reported in Chapter 2.  
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3.2.4 Solid state characterization 
Thermograms of powder samples were obtained using a differential scanning 
calorimeter (DSC mod. TC11, Mettler Toledo, Inc., Columbus, USA). Fusion temperature 
and enthalpy were calibrated with an indium standard (melting point 156.6°C). The samples 
(±5 mg) were accurately weighed, crimped in an aluminium pan and heated from to 25 to 
300°C at 10°C/min, under nitrogen purge of 50 mL/min. Diffraction patterns were obtained 
using an X-ray diffractometer (mod. D8 Discover, Bruker AXS, Inc., Madison, USA) with a 
Cu sealed tube source. Samples were placed in the holder and flattened with a glass slide to 
assure a good surface texture. The measuring conditions were as follows: Ni-filtered CuK 
radiation, λ = 1.54 Å, 2θ angle ranging between 5° and 70° with a scan rate of 3 s/step and a 
step size of 0.2°. DSC and X-ray analyses were performed in three replicates for each batch of 
material. 
3.2.5 Solvent residue analysis 
The acetone residue was measured using a head space sampler (mod. 50 Scan, Hewlett 
& Packard, Palo Alto, CA, USA) coupled to a gas chromatograph interfaced with a flame 
ionization detector (GC-FID, mod. 6890 Agilent Series, Agilent Technologies Inc., 
Wilmington, DE). Acetone was separated using a fused-silica capillary column 30 m length, 
0.25 mm internal diameter, 0.25 µm film thickness (mod. DB-1, J&W, Folsom, CA, USA). 
The oven temperature in the GC was set to 40°C for 8 min. The injector was maintained at 
180°C (split mode, ratio 1:1) and Helium was used as the carrier gas (7 mL/min). Head space 
conditions were: equilibration time 60 min at 100 °C, pressurization time 2 min, loop fill time 
1 min. Head space samples were prepared in 10 mL vials filled with 3 mL of suspension.  
3.2.6 Drug loading & release 
Drug loading was measured by dissolving a known mass (5 mg) of microspheres in 
2mL of acetone. Samples were stirred for 1 h at 100 rpm to ensure the complete dissolution of 
the polymer. Pure RA was also tested to verify its stability in acetone; no drug degradation 
was observed. The concentration of drug in the resulting solution was determined by HPLC 
(mod. Agilent Tech. 1200 series). The column was C18 (3.9 x 250 mm), packed with 10 µm 
particles size. Elution was performed with methanol/water (98:2 v/v) at a flow rate of 1 
mL/min. 20 µL were injected and the absorbance of the eluting compound was monitored at 
324 nm. The amount of measured drug was then converted in the effective drug loaded into 
microspheres as in the follows: 100 x (weight of monitored drug/weight of sample taken for 
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analysis). The encapsulation efficiency was calculated as 100 x (effective loading/theoretical 
loading). Since the solubility of RA in n-propanol-water solution (30:70 v/v) is about 0.03 
mg/mL, for each release test, 100 mg of microspheres were suspended in 500mL of this 
solution continuously stirred at 100 rpm in a 35°C incubator to maintain adequate sink 
conditions. The concentration of the released drug in the external medium was continuously 
detected by a UV probe at 324 nm (mod. Cary 50, Varian Palo Alto, CA). 
 
3.3 Results & Discussion 
3.3.1 Selection of the operating conditions 
When acetone, water, and glycerol are mixed together, the phase diagram of the ternary 
system shows a two phase region due to phase separation and to obtain a stable emulsion, the 
ternary mixture composition should lie in this region. To verify the influence of the position 
of the operating points on the emulsion stability, two different oil-water ratios were prepared 
of 20/80 and 10/90, with a given composition of the oily phase (acetone with 45% w/w of 
PLGA plus 3% of RA) and the water phase (glycerol/water 80/20 with 0.6% w/w of PVA). 
Figure 3.1 reports the ternary acetone-water-glycerol diagram in which two red dots indicate 
the position of the operating points selected for emulsions formulation. One point is located in 
the Phases I region (i.e., in the area of complete miscibility between the three components) 
and the second near the border of Phase II (i.e., in the two phases region). The emulsion with 
the o-w ratio of 20/80 (point 1, in Figure 3.1) was stable and led to well defined PLGA 
microspheres after the oily phase removal; whereas, the emulsion with the o-w ratio of 10/90 
(point 2, in Figure 3.1) produced only large polymer aggregates. These results mean that the 
emulsion with the o-w ratio of 10/90 is not stable and in the following part of the study only 
the o-w ratio of 20/80 is used. 
3.3.2 Comparison with the conventional liquid extraction  
In this study, the comparison of the extraction processes (liquid and supercritical) is 
proposed based on the characteristics of the microspheres obtained by SEE-B and by 
conventional liquid extraction (LEE). The same emulsions (o-w ratio 20:80) have been 
processed with the two technologies and the morphology of microspheres produced by SEE-B 
was in all cases spherical and no coalescing; however, collapsed particles were often 
produced by LEE. All SEE experiments were performed operating at 80 bar, 36°C, since at 
this process conditions, acetone is completely miscible in SC-CO2 [112]; whereas, the 
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solubility of the glycerol-water external phase in SC-CO2 is extremely small [113-114]; 
therefore, a selective extraction of the oily phase from emulsions, is expected. Other operating 
conditions used, were already described in Chapter 2. Solid PLGA/RA products obtained after 
SEE-B treatment of these emulsions are reported in the SEM images illustrated in Figure 3.2 
(a-b), respectively. 
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Figure 3.1. Phase diagram of water-glycerol-acetone ternary system with the representation of operating 
points I: o-w 20/80 and operating point II: o-w 10/90. Experimental data adapted from Matsumoto et al., 
2008. 
 
(a) (b) 
Figure 3.2 a-b. SEM images of the microparticles obtained by SEE using emulsions with different o-w 
ratios; (a) well shaped microspheres using an o-w ratio of 20/80; (b) collapsed and connected microspheres 
using an o-w ratio of 10/90. Oily phase: acetone with 45% PLGA and 3% RA w/w (theoretical loading); 
water phase: glycerol-water 80:20 with 0.6% w/w of PVA.  
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An example of the different results obtained, is illustrated in the SEM images reported 
in Figure 3.3 (a-b), that are related to microparticles obtained from emulsions prepared with 
PLGA concentrations of 45% and RA content of 6%. The water phase was formed by 
glycerol-water (80:20) with 0.6% w/w of PVA. The SEM image in Figure 3.3b, shows large 
aggregates of microparticles. This phenomenon can be due to an inadequate amount of the 
extraction agent or an insufficient absorbing rate of the solvent leached from the solidifying 
microspheres, that may generate intra-particle adhesion [115]. On the contrary, the enhanced 
mass transfer characteristic of SC-CO2, generates a faster extraction avoiding particles 
adhesion, as confirmed by SEM image of microspheres reported in Figure 3.3a. Distribution 
data, encapsulation efficiency and solvent residues of the produced microspheres are 
summarized in Table 3.1. For example, starting from an emulsion with a Droplet Mean Size 
of 4.1 m (SD ±2.2), microspheres with a mean size of 3.6 m (SD ±1.9) were obtained by 
SEE-B and with a mean size of 4.3 m (SD ±2.3) were produced by conventional LEE. The 
encapsulation efficiency into PLGA microspheres was 80% when operating with SEE-B and 
73% when the conventional extraction process was used. Both encapsulation values can be 
considered excellent and indicate that the emulsion formulation proposed is stable.  
 
SEE-B (a) LEE (b) 
Figure 3.3a-b. SEM images of PLGA/RA microspheres produced by: (a) SEE-B; (b) conventional Liquid 
Extraction (LEE). Emulsion (o-w ratio 20/80) composition: oily phase, acetone with PLGA 45% w/w; 
water phase, glycerol-water 80:20 and 0.6% w/w of PVA.  
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Table 3.1. Results of liquid emulsion extraction (LEE) and supercritical extraction (SEE-B) proposed in 
term of PSDs produced using an o-w emulsion (ratio: 20:80).  
 
PLGA content in oil (%) 45 
Teoretical drug loading (%) 3 
Distribution data DSDs PSDs 
Process layouts --- LEE SEE-B 
MS (µm) 4.1 4.3 3.6 
SD (µm) ± 2.2 ± 2.3 ± 1.9 
Recovery (%) ---- 65 56 
Solvent Residue (ppm) ---- 50000 3591 
Effective drug Loading (%) ---- 2.2 2.4 
Encapsulation efficiency (%) ---- 73 80 
 
Solvent residue monitored after SEE-B processing was 3591 ppm and was significantly 
lower than the value found after the conventional LEE that produces suspensions with an 
acetone residue of the order of 50000 ppm. As a consequence, more complex downstream 
processes are required for particle recovery such as, prolonged washing with pure water, as 
well as, acetone/glycerol/water mixture separation to recover the pure solvents. Also the 
processing time is different because SEE-B process requires only 60 min against the 160 min 
of the LEE, to process the same quantity of emulsion.  
3.3.3 Batch vs. continuous operation  
Emulsions with o-w ratio of 20:80 were formulated fixing the PLGA concentration in 
acetone at 45% w/w and varying the RA theoretical loading from 3, 6 and 10 % w/w. They 
were treated using the two different SEE layouts: batch (SEE-B) and continuous (SEE-C). All 
the PSDs data of the microspheres recovered using the two processes layout and other 
significant process information are reported in Table 3.2. The DSDs data of the emulsions 
treated are also reported, for comparison purposes. Microsphere size and distribution are the 
first parameters considered for the comparison. Looking at the PSDs data of the microspheres 
produced by SEE-B and SEE-C, it is evident that they are similar and the process layout does 
not have a significant effect on the PSDs. Indeed, starting from an emulsion with a Droplet 
Mean Size of 3.5 m (SD ±1.9), microspheres with a mean size of 3.2 m (SD ±1.4) were 
obtained by SEE-B and with a mean size of 3.3 m (SD ±1.9) were produced by SEE-C. The 
drug encapsulation efficiency measured for all the microdevices produced were very good and 
ranged between 80 and 90%.  
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Table 3.2. Results of different SEE process layouts batch (B) and continuous (C) proposed in term of PSDs 
of the microspheres produced using an o-w emulsion (ratio 20:80).  
 
PLGA content in oil (%) 45 
Teoretical drug loading (%) 3 6 10 
Distribution data DSDs PSDs DSDs PSDs DSDs- PSDs 
Process layouts --- SEE-B SEE-C --- SEE-B SEE-C --- SEE-B SEE-C 
MS (µm)  3.5 3.2 3.3 4.9 3.5 3.2 6.2 5.9 4.3 
SD (µm) ± 1.9 ± 1.4 ± 1.9 ± 2.2 ± 1.4 ± 1.6 ± 4.1 ± 3.6 ± 2.3 
Processing Time (min) --- 60 10 --- 60 10 --- 60 10 
Recovery (%) --- 56 85 --- 48 90 --- 60 89 
Solvent Residue (ppm) --- 3591 1075 --- 4100 1025 --- 3600 980 
Effective drug Loading (%) --- 2.4 2.7 --- 5.1 5.2 --- 8.7 8.8 
Encapsulation efficiency (%) --- 80 90 --- 85 87 --- 87 88 
 
As indicated in a previous chapter, the two process layouts can show different recovery 
efficiency, phase mixing and, therefore, processing time. Indeed, the batch process allowed 
the recovery of maximum 56% of the charged material because part of the microsphere 
suspension was lost in the gas stream released during the final depressurization step and part 
was not recovered from the walls of the precipitator. On the contrary, the continuous process 
allowed the recovery of about 85-90% of the charged material. The solvent residue after the 
continuous process was about 1000 ppm, a considerably lower value than the ones measured 
in the batch SEE operations that ranged between 2000 and 4000 ppm. This result confirms 
that the continuous process produces a better contact between the two phases (emulsion/SC-
CO2), enhancing mass transfer. The final remarkable result is the processing time: i.e., 
considering as a reference time, the residence time of the liquid phase in the packed column, 
the continuous processing requires a residence time of the emulsion/suspension in the column 
of only 10 min; whereas, about 60 min is the residence time of the emulsion/suspension 
treated by SEE-B and 160 min are necessary to perform the conventional liquid-liquid 
extraction. 
3.3.4 Microspheres size tailoring and solid state characterization 
PLGA concentration in the acetone oily phase was varied between 45 and 55% w/w at a 
fixed drug concentration of 3% w/w and the influence on microspheres size distribution and 
loading efficiency was studied, in the case of the continuous SEE process. The emulsion o-w 
ratio and the composition of the water external phase was maintained constant, as previously 
reported. The PSDs data of the produced microspheres are reported in Table 3.3, together 
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with the DSDs data of the corresponding emulsions, for comparison purposes. The variation 
of PLGA concentration in the oil phase, in the range explored, always produced emulsions 
with stable and non-coalescing droplets, as illustrated in the optical microscope image 
reported in Figures 3.4a-b. The correspondent microspheres obtained after SEE-C operation 
are reported in the SEM images shown in Figures 3.4c-d. Microspheres with a mean size of 
3.2 m (SD ±1.4) were obtained at the PLGA percentage of 45% w/w and with a mean size of 
4.0 m (SD ±2.1) at the PLGA percentage of 55% w/w charged in the oily phase, 
respectively.  
 
Table 3.3. DSDs and PSDs of microspheres produced by SEE-C using an o-w emulsion (ratio 20:80; PLGA 
concentration: 45% and 55% w/w; drug loading: 3% w/w).  
 
PLGA content in oil (%) 45 55 
Teoretical drug loading (%) 3 
Distribution data DSD PSD DSD PSD 
MS (µm) 3.5 3.3 4.5 4.0 
SD (µm) ± 1.9 ± 1.9 ± 2.4 ± 2.1 
Recovery efficiency (%) -- 85 -- 90 
Solvent Residue (ppm) 
[ppm] 
-- 1075 -- 1006 
Effective drug Loading (%) -- 2.7 -- 2.5 
Encapsulation efficiency (%) -- 90 -- 83 
 
Thermal analysis (DSC) was performed on the produced microspheres and on raw 
PLGA and RA, for comparison purposes. The corresponding thermograms are reported in 
Figure 3.5. PLGA (75:25) shows a glass transition that remains relatively constant (onset 
39.98°C; endset 45.32°C) in all the observed samples and the polymer decomposition occurs 
above 300°C. Raw RA shows an endothermic peak at about 58°C, due to its melting. The 
PLGA/RA microspheres show the same degradation event of the unprocessed polymer 
confirming that the supercritical process does not modify the polymer structure; whereas, the 
characteristic peak of RA is no longer visible in the microspheres, even when the drug 
effective loading was 8.8% w/w. This fact suggests that the drug is dissolved into the PLGA 
matrix. X-ray analyses were performed to obtain information about the solid state of the 
produced materials. The diffraction patterns of microparticles are reported in Figure 3.6. The 
XRD of raw polymer and RA are also reported, for comparison. XRD analyses show that all 
the particles obtained are amorphous due to the fast polymer precipitation inside the droplets 
during the oily phase extraction.  
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Figure 3.4a-d. Optical microscope images of the emulsions and SEM images of the related microspheres 
produced by SEE-C using emulsions (o-w ratio 20/80) with different PLGA content in the oily phase of 45 
(a-b) and 55% (c-d) w/w, respectively. The theoretical drug loading was of 3% RA w/w (effective loading 
2.7 and 2.5 % respectively); water phase, glycerol-water 80:20 and 0.6% w/w of PVA. 
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Figure 3.5. DSC traces of PLGA/RA microspheres produced by SEE with a MS of 4.3 m (SD ± 2.3 m) 
and effective RA loading of 8.8% w/w. Traces of untreated PLGA and RA are also reported, for 
comparison.  
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Figure 3.6. XRD patterns of PLGA/RA microspheres produced by SEE with a MS of 4.3 m (SD ± 2.3 
m) and effective RA loading of 8.8% w/w. Patterns of untreated PLGA and RA are also reported, for 
comparison.  
  
66 
 
3.3.5 Drug release study 
PLGA microspheres produced by SEE-C and with RA effective loadings of 2.7, 5.2 and 
8.8% w/w, were tested for drug release studies in a modified media [116] of water/n-propanol 
(70:30) at 35°C (microspheres distribution data are reported in Table 3.2). The release 
profiles are illustrated in Figure 3.7; in the same figure the dissolution rate of pure RA is also 
reported. Drug release was monitored only for 6 days, since RA degradation in the external 
medium was observed when longer times were used. Release profiles obtained at different 
loadings show that, when the RA content is increased, a slower drug release is obtained: i.e., 
90% of RA is released in 6 days when the drug loading is 2.7% w/w; whereas, in the same 
time, only 40% and 10% of the drug is released when the charge is 5.2% and 8.8% w/w, 
respectively.  
It is known from the literature, that drug release from PLGA can be described in two 
steps; the first one reflects the diffusion controlled mass transfer of the drug accessible at the 
solid/dissolution medium interface and the second step reflects the release of drug entrapped 
in the polymer during its bulk degradation [117-118]. The release behavior at different drug 
loadings observed in this study can be explained considering the low solubility of RA in the 
release medium (see measured solubility data in the Methods section). Indeed, as suggested 
by Lee [119], when the concentration of the drug in the polymer microsphere is higher than its 
equilibrium solubility in the external medium, two moving fronts can be established 
(diffusion followed by bulk erosion) and they are synchronized (the second front will be 
influenced by the first one). In our case, the diffusion front is very slow and can move towards 
the internal of the particles only when the concentration in the solid phase decreases to values 
lower than the equilibrium value; as a consequence, the higher is the drug concentration in the 
polymer, the slower is the movement of the diffusion front [120]. 
An attempt to describe this PLGA release mechanism (diffusion/degradation controlled) 
was also performed using the mathematical model proposed by Corrigan and Li [121] that 
takes into account the two different release steps with the following equation (1):  
degFFF Dtot 
    (1)
 
where Ftot is the total fraction of drug released at a given time; FD is the initial diffusion 
contribution of drug accessible at the solid/dissolution medium interface (mass percentage) 
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and Fdeg is the contribution of drug (mass percentage) entrapped in the polymer, whose 
release depends only to the polymer bulk degradation. The authors also assumed that the drug 
is dispersed as a separate phase into the polymer. As a consequence, the component FD can be 
described as: 
)1(inf
Kdt
DD eFF

   (2) 
where FDinf  is the diffusion contribution at infinite time and Kd is the first order constant 
associated with the diffusion controlled release that can be directly proportional to the 
apparent diffusivity of the drug in the system. Kd is equal to DACs/FDH1 where D and Cs are 
the diffusion coefficient and the solubility of the drug respectively, A is the surface area of 
drug available for dissolution and H1 is the apparent aqueous diffusion boundary layer 
thickness. The apparent diffusivity takes into account the drug transfer through the polymer 
and the drug transfer through the external medium [122]. 
The second component of the equation (1), Fdeg, is related to polymer bulk erosion and 
can be described by equation (3): 
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where tmax and K are, respectively, the time of the maximum drug release rate and the 
first order rate constant of drug release, mediated by polymer degradation. Therefore, the 
fractional drug release versus time profile can be described by equation (4):  
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Equation (4) allows the estimation of the parameters Kd FD, K and Tmax by a non linear 
least square fitting. The calculated parameters obtained by fitting the experimental data with 
equation 4 are reported in Table 3.4. The model also gives a fair good representation of the 
RA release profiles, as can be seen from the continuous curves reported in Figure 3.7.  
Looking at the kinetic parameters reported in Table 3.4, it can be observed that Kd 
values decrease by increasing the drug loading (from 0.0085 to 0.0011 days
-1
 with a drug 
loading of 2.7 and 8.8%, respectively); this behavior should mean that increasing the loading 
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of a low solubility drug, the apparent diffusivity of the drug will decrease and, therefore, the 
release kinetic constant is slower. On the contrary, the FDinf values increase from 0.56 to 0.96 
when the drug loading is increased from 2.7 to 8.8%. FDinf represents the fraction of drug 
released by simple diffusion; i.e., this trend is reasonable considering that increasing the drug 
loading, diffusion becomes the prevalent phenomenon, controlling the drug release. Tmax 
values were directly evaluated from the experimental curves and fixed to 1.5, 3.2 and 3.5 
days. The timing of the maximum drug release rate should be explained taking into account 
that bulk erosion front follows the diffusion front, as stated before; therefore, when the 
diffusion front is delayed (by higher drug loading of the low soluble drug) also the Tmax value 
increases. Finally, the bulk erosion kinetic constant K was calculated at 0.68 days
-1
 and was 
maintained constant in all data fitting because it should be independent from the drug loading, 
being only related to the depolymerization reaction.  
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Figure 3.7. Release profiles from PLGA microspheres with effective RA loadings of 2.7% (□), 5.2 % (), 
8.8 % (○). The release profile of pure RA is also proposed, for comparison (*). Curve fittings obtained 
using equation (4) are reported, as continuous line.  
 
Table 3.4. Best fit model parameters estimated from RA release profiles obtained from PLGA 
microspheres.  
 
Effective drug Loading (%) Fd Kd [day-1] K [day-1] Tmax [day] R
2
 
2.7 0.56 (± 0.01) 0.0085 ± (0.0005) 0.68 1.5 0.97 
5.2 0.89 (± 0.003) 0.002 ± (0.001) 0.68 3.2 0.93 
8.8 0.96 (± 0.001) 0.0011 ± (0.00002) 0.68 3.5 0.94 
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3.4 Conclusions & Perspectives 
Supercritical fluids emulsion extraction technology offers a new strategy in the 
biopolymer microsphere production with a better particle size control also when labile 
compounds, such as retinyl acetate, are processed. Taking advantage of the enhanced mass 
transfer of the supercritical solvent, spherical PLGA microspheres, with less residual solvent 
respect to the conventional process, can be successfully produced with an excellent drug 
encapsulation. The upgrade of SEE technology into the continuous process layout (SEE-C) 
allows a higher throughput with smaller plant volumes, eliminating all the batch-to batch 
repeatability drawback. This technology can be proposed as a process innovation that may 
allow the fast production of tailored PLGA/drug microspheres with an excellent control of 
drug release. 
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Chapter 4. PLGA-PAMs produced by SEE-
C: Study on Bioactive Signal Release in 
Myoblast Culture 
 
4.1 Introduction 
Cell therapy promises to become a major therapeutic option in regenerative medicine, 
although relevant questions about cell homing, survival and differentiation into the host tissue 
are still open. Pharmacologically Active Microcarriers (PAMs) may contribute to face these 
problems since these biocompatible and/or bioresorbable microdevices can deliver a specific 
bio-signal (such as growth factors) they are loaded with [123-125], inside to a more complex 
3D scaffold with cells onboard. In this configuration they may also act as transient 
microdevices influencing cell fate into the host tissue, as recently reported [126-127]. 
Poly-lactic-co-glycolic acid (PLGA) has received great interest as a hydrolytically 
degradable and bioresorbable polymer [128] for the development of nano- and micro-devices 
to be used in tissue engineering [129] being among the few biopolymers approved by the 
Food and Drugs Administration (FDA) for injectable/implantable use in human body. As an 
example, PLGA microcarriers have been reported as a moldable scaffold for cartilaginous 
tissue engineering [130-132] and when RGDS peptides were immobilized onboard they were 
able to promote chondrocyte attachment, proliferation, viability and sulfated 
glycosaminoglycans secretion [133].  
In this light, considerable scientific efforts have been made for the development of 
robust and reproducible technologies to manufacture these PLGA microcarriers, in order to 
better control their size distribution, as well as, their bioactive molecule loading and release. 
The most common method to encapsulate biomolecules such as, peptides or proteins, into 
PLGA microspheres is the use of double water-oil-water emulsions followed by solvent 
evaporation. This technique is easy to set up at the laboratory scale but its success is 
hampered by the limited efficiency and the lack of batch-to-batch reproducibility in 
encapsulation of the bioactive molecules [134]. Moreover, due to the long evaporation step 
required, the encapsulated protein may form insoluble precipitates when exposed to the 
water/organic solvent interfaces of emulsion [135-136], or may diffuse to the continuous 
 71 
external aqueous phase leading to protein loss [137], although this last problem can be 
partially cleared adding hydrophilic components, such as glycerol, that participate to the 
formation of a stable internal phase of double emulsification [138]. 
The aim of this work is to produce high quality PLGA-PAMs to be used for sustained 
release of bioactive signals in a culture medium. Different water-oil-water emulsions, 
obtained using ethyl acetate as oily phase solvent, will be prepared and processed by SEE-C 
for the production of microdevices with controlled size and distinct bioactive protein (bovine 
serum insulin) loading; they will also characterized in terms of morphology, size and protein 
encapsulation efficiency. The insulin release profile in different media (phosphate saline 
buffer and cell culture medium) will be monitored and fitted using a mathematical model to 
give a better description of the two different release steps (diffusion and degradation) that are 
typical of the PLGA devices. Finally the H9c2 cell line (rat embryonic ventricular myoblasts) 
[139] will be cultured in presence of insulin-loaded PLGA-PAMs to monitor cell viability and 
proliferation as sustained by bioactive insulin release in serum-free culture medium. 
 
4.2 Apparatus, Materials and Methods 
4.2.1 Materials 
CO2 (purity 99.9%) was purchased from SON (Naples, Italy). Poly (lactic-co-glycolic) 
acid (PLGA 50:50; RESOMER
®
 RG 504H; Mol wt: 38000-54000; inherent viscosity 0.45-
0.60 dl/g) was supplied from Boehringer Ingelheim (Germany). Polyvinyl alcohol (PVA, Mol 
wt: 30,000–55,000), Insulin from bovine pancreas (INS, purity 99.9%) and glycerol (GLY, 
purity 99%) were obtained by Sigma-Aldrich Co. (Milan, Italy). Trifluoroacetic acid (TFA) 
and HPLC grade acetonitrile were purchased by Carlo Erba Reagents (Milan, Italy).  
4.2.2 Emulsion Formulations 
The water-oil-water emulsion ratio was fixed at 1:19:80. Particularly, a fixed amount of 
insulin was dissolved into an aqueous/TFA GLY solution (250 µl of GLY and 750 µl of water 
with 0.1% TFA) with PVA concentration of 0.04% w/w and 1 mL of this solution was added 
into the oily phase formed by ethyl acetate (EA) and PLGA at 10% w/w. Insulin is only 
sparingly soluble in water and it is mandatory to set the pH below the protein isoelectric point 
(pI=5.5), therefore, an acid environment obtained with TFA was used at pH 2.5 to assure that 
ion-pairing takes place with all basic insulin functionalities. The primary w1-o emulsion was 
obtained by ultrasonication with a digital ultrasonic probe (mod. S-450D, Branson Ultrasonics 
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Corp., Danbury, CT, USA) at 50% of amplitude for 90 sec. The secondary w1-o-w2 emulsion 
was obtained mixing the primary emulsion with an outer water phase of saturated aqueous 
PVA solution (0.6% w/w in water) by high-speed homogenizer (mod. L4RT, Silverson 
Machines Ltd., Waterside-Chesham Bucks, UK). An external ice bath was always used to 
keep the emulsion temperature lower than 10°C. All the emulsions were prepared with filtered 
or autoclaved solutions.  
4.2.3 Production by SEE-C Technology in GMP sterile conditions 
SEE-C apparatus was already described in details in Chapter 2. However, procedures 
for sterile PAMs collection were developed in this part of the work: i.e., during the runs, the 
PAMs suspension is continuously collected at the bottom of the extraction column, washed 
with sterilized water by centrifugation and then liophilized. At the end of each run, the 
column is washed with pure acetone and sterilized water to eliminate any processing residue 
from the internal packing surface and also to sterilize it. Ultrafiltered or autoclaved gas and 
liquids coupled with standardized operative procedures in a continuous operation apparatus 
assured PAMs sterility.  
4.2.4 Droplets & PAMs characterization 
The droplets in the emulsions were observed using an optical microscope (mod. BX 50 
Olympus, Tokyo, Japan) equipped with a phase contrast condenser. Microspheres shape and 
morphology were analyzed by Field Emission-Scanning Electron Microscope (FE-SEM mod. 
LEO 1525, Carl Zeiss SMT AG, Oberkochen, Germany).  
The specimens were prepared by mounting the dry sample on aluminium stubs and 
coating it with a gold-palladium film (layer thickness 250Å) using a sputter coater (mod. 108 
A, Agar Scientific, Stansted, UK). Droplet Size Distributions (DSDs) and Particle Size 
Distributions (PSDs) were measured by a dynamic light scattering (DLS, mod. Mastersizer S, 
Malvern Instruments Ltd., Worcherstershire, UK). Analyses were performed immediately 
after the preparation of emulsions and microdevices suspensions, using several milligrams of 
each sample. Mean size was measured ten times for each sample and the distributions 
proposed are the mean of the replicates. Droplets and particle size are expressed as volume 
Mean Diameter (MD, µm) and Standard Deviation (SD) of values collected.  
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4.2.5 Protein loading determination  
The amount of protein loaded into the microspheres was monitored using the procedure 
described by Bilati et al. [140]. Briefly, 10 mg of dried microspheres were dissolved in 600 
µL of acetonitrile in centrifuge tubes and sonicated until the complete transparency of the 
solution. Then, 1400 µL of water containing 0.1% TFA (0.1% aqueous TFA solution) were 
added dropwise to the corresponding centrifuge tube to dissolve insulin. The remaining 
undissolved PLGA was separated by centrifugation at 2000 rpm for 2 minutes. The resulting 
clear supernatant solution was directly analyzed at room temperature by HPLC (model 1200 
series; Agilent Technologies Inc.) equipped with a LiCrosphere C18 column (250×4.6 mm), 
packed with 5 µm particles size of 100 Å pore size. The mobile phase was composed of 
acetonitrile/water mixture (32:68 v/v) containing 0.1% v/v TFA. The flow rate was 0.9 
mL/min, the injection volume of the test sampled was 20 µL and the detecting wavelength 
was 214 nm. The amount of insulin in solution was calculated by means of a calibration curve 
and then converted in the effective insulin loading as the amount (mg) of insulin charged in 
PLGA-PAMs (g). Encapsulation efficiency (EE) is the ratio of the final insulin loading to the 
nominal one. A known amount of pure insulin was also tested to verify its stability in water 
with 0.1% TFA and no protein degradation was observed. Each sample was assayed in 
quadruplicate and a good reproducibility was observed. 
4.2.6 In Vitro protein release studies  
In vitro release kinetics of insulin from PAMs were evaluated by suspending accurately 
weighed 20 mg of dried microspheres in 2 mL of Phosphate-Buffered Saline (PBS, 100 mM, 
pH 7.4) or 2 mL of Dulbecco's Modified Eagle Medium (DMEM) used for cell culture, in a 
centrifuge tube. The tubes were then placed in an incubator at 37°C and stirred continuously 
at 50 rpm. At fixed time intervals, the samples were centrifuged at 4000 rpm for 15 minutes 
and the supernatant was completely withdrawn and replaced with fresh media to maintain sink 
conditions. The amount of released protein was determined by measuring the protein 
concentration in the supernatant using HPLC method. Release experiments were performed in 
triplicate and the proposed curves are the mean profiles obtained. The percentage of released 
insulin was defined as the mass of protein released divided by the total mass of the charge. 
4.2.7 PAMs Sterilization & Cell Culture 
Microspheres sterility is assured by a good manufacture practice protocol adopted 
during their production by SEE-C. However, before their use in cell cultivations, an additional 
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soaking in 1% v/v penicillin/streptomycin (PEN/STR) was performed for 15 min; PLGA 
microspheres were then recovered by centrifugation and washed with PBS. Rat embryonic 
ventricular myoblasts (H9c2 cell line) were used to test cell viability and proliferation as 
sustained by bioactive insulin release from PLGA microspheres in serum-free culture 
medium. An optical microscope image of the cells is reported in Figure 4.1a. Cells were 
routinely grown to 80% confluence at 37°C in an atmosphere of 5% CO2 prior to passage and 
seeding for experiments in a standard medium formed by DMEM with 1% of L-glutammine 
solution (GLU, 0.1 ug/mL) supplemented with 10% v/v of fetal bovine serum (FBS) and 1% 
v/v PEN/STR. The Alamar blue (AB) test was used to monitor cell viability and proliferation 
by direct addition to culture medium at different time points (24 and 72 h). The redox reaction 
where AB is reduced by the cells was measured by fluorescence readings (Ex/Em = 540/590 
nm) in a multilabel multiplate Infinite M200 reader (TECAN, Cernusco sul Naviglio, MI, 
Italy) [141].  
Cell viability and proliferation were monitored in a DMEM serum free medium added 
with insulin-loaded microspheres (see Figure 4.2b). Each sample was assayed in 10 
replicates. 
 
(a)          (b) 
Figure 4.1a-b. OM image of 80% confluent embryonic ventricular myoblasts (cell line H9c2) obtained 
from rat cultivated in a standard medium(a); PLGA microspheres were suspended in the cell medium 
with cells stuck at the bottom of the culture flask (b). 
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4.3 Results & Discussion 
To ensure selective extraction of ethyl acetate from the oily phase of the emulsion, SEE-
C operative conditions, in terms of pressure and temperature, were chosen taking into account 
the high pressure vapor-liquid equilibrium diagram (VLE) of the binary system ethyl 
acetate/CO2. Temperature of 37°C and pressure of 80 bar were selected to work above the 
critical point of the binary mixture considered, as described in detail in Chapter 2.  
4.3.1 PLGA-PAMs loaded with Insulin 
Bovine serum insulin was loaded into PLGA microdevices as a model compound to be 
used as a cell medium supplement (substituting for fetal bovine serum). Indeed, insulin has 
been reported to have the same positive effect of IGF in myoblast cultures and to interact with 
the same cell receptors [142]. As a consequence, theoretical loading values of 5 and 10 mg/g 
were selected because close to the ones used for the encapsulation of growth factors into 
biopolymer microdevices. 
A w1-o-w2 double emulsion (see “Apparatus, Materials and Methods” section for the 
exact composition) with a fixed PLGA content in the oily phase of 10% w/w and insulin 
theoretical loading of 5 mg/g was prepared by varying the stirring rate during the formation of 
the secondary o-w2 emulsion from 2800 to 1400 rpm for 3 min; different droplets with MDs 
of 3 µm (± 1.2 µm) and 5 µm (± 2.3 µm), respectively, were obtained. The emulsions were 
processed by SEE-C just after their preparation, obtaining two batches of PAMs with different 
MDs of 2 µm (± 0.9 µm) and 3 µm (± 2.2 µm), respectively, because of droplets shrinkage 
between 33% and 40% of their volume. Examples of the produced PLGA-PAMs are reported 
in Figures 4.2a-c, where FE-SEM images of the obtained microdevices are illustrated. In both 
cases, the insulin encapsulation efficiency was of 60%, leading to the production of PLGA-
PAMs with an insulin content of 3 mg/g of PLGA. Another batch of PAMs was produced 
with a MD of 3 µm (± 1.9 µm) but loading the double amount of insulin (10 mg/g). In this 
case, the encapsulation efficiency was of 58%, leading to PAMs with an insulin content of 6 
mg/g. A batch of empty PLGA-PAMs with a MD of 2 µm (± 0.7 µm) was also produced to be 
used for the toxicity and control tests; in this case, an o-w emulsion with a PLGA content in 
the oily phase of 10% w/w and obtained using a stirring rate of 2800 rpm was processed by 
SEE-C. The PSDs curves of the three different PLGA-PAMs batches charged with insulin are 
illustrated in Figure 4.3. It can be observed that decreasing the stirring rate from 2800 rpm to 
1400 rpm during the emulsions generation, the derived particle mean size increases and 
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distribution slightly enlarges. The encapsulation efficiencies (EE) and insulin loadings 
(theoretical, TL, and effective, EL) are summarized in Table 4.1. They can be considered 
very good and higher than the values reported in the related literature especially when ethyl 
acetate was used as oily phase solvent; indeed, ethyl acetate is normally considered a solvent 
that leads to the worst encapsulation efficiency due to the high tendency of droplets to 
coalesce during the solvent evaporation step and, therefore, not suggested for microspheres 
production. Indeed, especially when a double emulsion must be used to encapsulate a water 
soluble compound, the use of dichloromethane (that is a more toxic solvent) is recommended 
[143-144]. However, using the SEE-C technology, good encapsulation efficiencies were 
obtained with respect to the conventional processes, also using ethyl acetate (that is a less 
toxic solvent if compared with dichloromethane) in the emulsion formulation. Moreover, 
when a double emulsion is processed for microspheres production, the coalescence between 
the inner and outer water phase may produce the leakage of the load water soluble molecules. 
In the emulsions used in the present work, glycerol was added to the internal water phase to 
increase the inner phase viscosity and reduce the insulin diffusion to the outer water phase, as 
suggested by some authors [145]. The presence of glycerol, into the inner phase, coupled with 
the very fast SEE-C processing are considered responsible of the very good encapsulation 
efficiencies obtained. 
 
Table 4.1. Characteristics of the PLGA-PAMs produced by SEE-C technology: Mean Diameter (MD) and 
Standard Deviation (±), theoretical (TL) and effective (EL) insulin loading and encapsulation efficiency 
(EE); percentage amount of insulin released in DMEM media after 72 h (that corresponds to the period 
selected to monitor the cell growth on PAMs).  
 
PAMs_MD m TL mg/g EE % EL mg/g Insulin released at 72 h % 
1.8 (± 0.9) 5 62 (±2.9) 3 (± 0.03) 50.1 
3.2 (± 2.2) 5 60 (±1.5) 3 (± 0.02) 27.5 
2.8 (± 1.9) 10 58 (±3.4) 6 (± 0.07) 73.4 
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(a) 
 
(b) 
 
(c) 
 
 
Figure 4.2a-c. FE-SEM images of PLGA-PAMs obtained after the emulsion processing by SEE-C at 80 
bar and 37°C. (a) PAMs with MD of 2 µm and loading of 3 mg/g; (b) PAMs with MD of 3 µm and loading 
of 3 mg/g; (c) PAMs with MD of 3 µm and loading of 6 mg/g. 
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Figure 4.3. PSDs of the insulin-loaded PLGA-PAMs batches tested.  
 
4.3.2 In Vitro Insulin Release Study from PAMs 
It is known from the literature that drug release from PLGA can be described in two 
steps; the first one reflects the diffusion controlled mass transfer of the drug accessible at the 
solid/dissolution medium interface and the second step reflects the release of drug entrapped 
in the polymer by its bulk degradation, as discussed in Chapter 3. PLGA-PAMs of different 
MDs (2 and 3 µm) and protein loadings (3 and 6 mg/g) were tested to monitor the insulin 
release profiles at 37°C in two different release media: PBS and DMEM. The PBS medium is 
the one recommended by the US Pharmacopea for the drug release study; therefore, was used 
to compare our release profiles (and the calculated kinetic constants) to the ones reported in 
the literature of PLGA microspheres with a polymer composition of 50:50 and charged with 
water soluble compounds. The release profiles in DMEM medium were also studied in order 
to understand the amount of insulin released from PAMs at fixed time during the cell culture.  
The release profiles of PAMs with different MDs of 2 and 3 µm and loaded with 3 mg/g 
of insulin in PBS are reported in Figure 4.4a. Fittings curves are also illustrated as dashed 
lines. Both sizes showed in PBS a fast release in the first days, followed by a more sustained 
release up to the subsequent 28 days. Microspheres with mean size of 2 µm released 80% of 
the total amount during the first day, whereas, microspheres with mean size of 3 µm released 
50% of molecule loaded in the first day. When a higher insulin loading of 6 mg/g was tested 
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from microspheres with a mean size of 3 µm, an even faster release was observed and almost 
the 90% of the charge was released in the first day (see Figure 4.4b). Insulin release, in the 
following days, was slower for microspheres with a larger size (3 m); whereas, higher 
loadings (6 mg/g) generated a faster release. This last behavior is in agreement with the 
results proposed by Corrigan and Li [121] reporting that the highest loading gave the fastest 
protein release throughout the same period and can be expected when the diffusion controlled 
mass transfer is prevalent. The release profiles produced in DMEM medium are reported in 
Figures 4.5a-b. In this case, microspheres with mean size of 2 µm released the 35% of the 
total amount during the first day; whereas, microspheres with mean size of 3 µm released in 
the same time interval only the 9% of the load (insulin loaded 3 mg/g). Increasing the insulin 
loading to 6 mg/g ( microspheres mean size of 3 µm), again a more fast release was observed 
and the 70% of the charge was released in the external media in the first day. In DMEM 
medium, the overall release was almost completed in 24 days. It’s worth noting that a slower 
release was observed in DMEM with respect to PBS; this behavior can be explained 
considering their different composition and the possibility that in DMEM the protein release 
by desorption is delayed [146]. Moreover, the shape of the insulin release profiles obtained in 
DMEM illustrated a multistep release mechanism with as initial fast release of the protein 
adsorbed at the microspheres surface, followed by its sustained release from the internal 
polymer layers largely enhanced by the depolymerization reaction. From the release kinetics 
obtained in DMEM it can be also observed that the controlled diffusion mechanism seems to 
be predominant in the first part of the release, where the curve profiles are clearly separated 
and larger microspheres sizes generated a slower release. The erosion mechanism seems to 
superimpose in the second part of the observed release, where the profiles overlap. 
An attempt to describe the observed release profiles was also performed using the 
equation previously discussed in Chapter 3. The model proposes a simplified mechanism to 
describe an overall release profile (typical of PLGA) that takes into account the diffusion 
controlled mechanism probably predominant in the first part of the release and a the 
diffusion/erosion ones that also involves the depolymerization reaction.  
The calculated parameters obtained by fitting the experimental data are reported in 
Table 4.2. The model also gives a fair good representation of the insulin release profiles, as 
can be seen from the dashed curves reported in Figures 4.4a-b and Figures 4.5a-b. Looking 
at the kinetic parameters reported in Table 4.2, for the release profiles monitored in PBS, it 
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can be observed that Kd decreases its values by increasing the PAMs sizes at fixed insulin 
loading of 3 mg/g (from 4.20 to 3.80 days
-1
 for PAMs sizes of 2 and 3 µm, respectively); 
whereas, with the increase of PAMs loading to 6 mg/g Kd increases its value to 5 days
-1
. This 
behavior is in agreement with the Kd expected behavior and should mean that increasing the 
loading, the apparent diffusivity will increase and, therefore, the release kinetic constant is 
higher; trends in Kd with microspheres size can be explained by the decrease in specific 
surface area and, thus, the amount of surface insulin available. The Kd values were in fairly 
good agreement with the ones proposed by Corrigan and Li [121] for the release of 
ovalbumin from PLGA microspheres with similar size and loading in PBS. Similar Kd values 
trend was also observed for the release profiles performed in DMEM; however, in this case 
the calculated Kd values were 0.32 and 0.13 days
-1
 for PAMs sizes of 2 and 3 µm charged with 
3 mg/g of insulin, respectively, so one order of magnitude smaller respect to the ones 
calculated for the release profiles in PBS.  
For the release profiles monitored in PBS, the FD values decrease from 0.82 to 0.63 
when the PAMs size is increased from 2 to 3 µm (loading 3 mg/g of insulin); FD represents 
the fraction of protein released by simple diffusion; therefore, this trend is reasonable 
considering that increasing the PAMs size, the diffusion pathway increases slowing the 
related release kinetics and, therefore, reducing the overall fraction of protein released by 
diffusion contribution. On the contrary, FD values increases to 0.94 when the insulin loading 
is increased to 6 mg/g for PAMs with a MD of 3 µm. The increase in FD with increased 
loading was attributed to the high concentration of drugs dispersed, which effectively 
increases the proportion of drug linked/adsorbed to the particle surface-liquid interface and is 
consistent with the observations of Gallagher and Corrigan [147]. The same trend, but less 
marked, was observed for the FD values calculated in DMEM medium. Tmax is the timing 
value of the maximum drug release rate and it was directly evaluated from the experimental 
curves and fixed at 14 and 11 days for all the curves obtained in PBS and in DMEM, 
respectively. Finally, the bulk erosion kinetic constant K was fixed at 0.15 days
-1
 for all the 
release performed in PBS and at 2.5 days
-1
 for all the ones performed in DMEM. These values 
were maintained constant in all data fitting for the two different media because K should be 
independent from the PAMs size or loading and mainly related to the PLGA 
depolymerization reaction.  
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Figure 4.4a-b. Comparison between the release profiles (days) of insulin from PLGA-PAMs suspended in 
PBS with: (a) different MDs of 2 and 3 µm and charged with the same loading of 3 mg/g; (b) different 
loadings of 3 and 6 mg/g and with the same MD of 3 µm. Dashed lines are model fittings. 
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Figure 4.5a-b. Comparison between the release profiles (days) of insulin from PLGA-PAMs suspended in 
DMEM with: (a) different MDs of 2 and 3 µm and charged with the same loading of 3 mg/g; (b) different 
loadings of 3 and 6 mg/g and with the same MD of 3 µm. Dashed lines are model fittings. 
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Table 4.2. Best fit model parameters estimated from insulin release profiles obtained from PLGA-PAMs 
of different sizes and protein loadings and in different media: phosphate buffer solution (PBS) and 
Dulbecco’s Modified Eagle Medium (DMEM).  
 
Medium 
PAMs_MD 
m 
EL 
mg/g 
FD 
Kd  
(day
-1
) 
K 
(day
-1
) 
Tmax 
(days) 
R
2
 
PBS 
2  3 0.823 4.20 0.15 14 0.98 
3  3 0.628 3.80 0.15 14 0.95 
3  6  0.943 5.00 0.15 14 0.88 
DMEM 
2  3 0.750 0.32 2.50 11 0.87 
3  3 0.732 0.13 2.50 11 0.99 
3  6  0.765 0.81 2.50 11 0.89 
 
4.3.3 Cells Viability, Adhesion & Growth on PAMs 
A number of 1000 cells/well were seeded and cultivated for 72 h to fit the Alamar Blue 
(AB) calibration curve. H9c2 myoblasts were cultivated in standard medium (see Materials & 
Methods” section) with or without 20 mg/mL empty PLGA microspheres. A comparable 
number of H9c2 cells (w/o PLGA microspheres  = 4100 ± 600, w PLGA microspheres = 3700 
± 800, 10 replicates, p < 0.05) was observed either in presence or absence of these devices, 
confirming their lack of toxicity when produced by SEE-C.  
Serum-free medium was used to evaluate H9c2 cell proliferation as sustained by 
bioactive insulin release when PLGA microspheres with a mean diameter of 3 µm and 3 mg/g 
of insulin load were tested. Loaded microspheres were added in scalar dilutions in order to 
obtain a theoretical insulin release up to 4, 8, 16 and 34 ug/mL, respectively, after 72 h. 1000 
cells/well were seeded and cultivated for 72 h in these different dilutions and their number at 
72 h is illustrated in Figure 4.6. As a control, cells were also cultivated in a serum free media 
with empty microspheres and, in this case, no cell proliferation was observed (see control 
results highlighted in red on Figure 4.6). On the other hand, a significant proliferation, 
consistent with the expected increasing insulin release was observed for the cells grown in 
serum-free media added with loaded microspheres. Particularly, best cell growth was 
observed at insulin concentration of 16 ug/mL; whereas, higher insulin concentration values 
seemed to have an adverse effect on the cell growth (cell number decreased from 8600 to 
5500 when the insulin concentration released was 34 ug/mL). This result is in agreement with 
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data reported in literature, where about 10 ug/mL is the recommended concentration using 
insulin as a growth supplement [148].  
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Figure 4.6. Number of cells growth after 72 h of incubation with different PLGA-PAMs amounts (MD of 3 
µm, insulin loading of 3 mg/g) against the insulin concentrations delivered in the serum free medium. The 
number of cell growth after 72 h in serum free media without PAMs is reported in red, for comparison.  
 
PAMs of different sizes but with the same loading showed different release kinetics, as 
reported previously. To evaluate the effect of the different release kinetics on cell growth, two 
different serum free media were prepared by adding a calculated amount of PLGA-PAMs 
with different MDs of 2 and 3 µm (insulin loading of 3 mg/g) to reach fixed insulin 
concentrations between 15-17 ug/mL after 72 h of release. The numbers of cell growth in 
these different media are illustrated in Fig. 4.7. Insulin concentrations in serum free medium 
ranging between 15-17 ug/mL allowed cell growth in all cases; however, the number of cells 
growth on PAMs of 2 µm was lower. The observed behaviour was probably due to the static 
condition of the cell cultivation, where PAMs with smaller size were observed to stick easier 
on the multiwell lateral surface probably preventing or reducing the insulin release. The 
observed behaviour should be taken into account for dynamic cell culture into a medium 
added with PAMs .  
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Figure 4.7. Cell growth on PLGA-PAMs of different size 2 and 3 µm (insulin loading of 3 mg/g) into serum 
free media with a fixed insulin concentration ranging from 15-17 ug/mL released after 72 h. 
 
4.4 Conclusions  
At the optimized operating conditions, a double w1-o-w2 emulsion can be easily 
converted in PLGA microspheres loaded with insulin by SEE-C technology. The process is 
completed in 5 min of residence time in the high pressure column, and biopolymer 
microdevices with controlled particle size and good encapsulation efficiencies can be 
obtained. The produced microspheres allowed a sustained insulin release, in cell culture 
medium, and were able of delivering bioactive insulin to sustain myoblasts growth in a 
serum-free medium. The results indicate SEE-C technology as a promising tool in the field of 
tissue engineering/regenerative medicine; indeed, these microdevices can be charged in more 
complex 3D scaffold with cell onboard for local signal delivery.  
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Chapter 5. Synergistic effect of sustained 
release growth factors from PLGA-PAMs 
and dynamic bioreactor flow on hMSC 
osteogenic differentiation in 3D alginate 
scaffolds 
 
5.1 Introduction 
New challenges of the regenerative medicine are the treating of bone injuries by seeding 
and growing a cell source on a 3D scaffold and implanting the scaffold and cells into the 
injury site [149]. Current changes in bone tissue engineering techniques are cell-containing 
scaffolds cultured in vitro prior of their implantation in order to promote cell proliferation and 
to allow for differentiation from stem cells into target cells. However, in vitro static culture 
techniques of 3D tissue engineering scaffolds showed several limitations including oxygen 
and nutrient gradients with lowered concentrations toward the centre of the scaffold, leading 
to cell death [150]. A bioreactor is often used to overcome this limitation of nutrient transfer. 
It is a culturing system designed to support or expand a population of cells through dynamic 
culture in a controlled environment. Different bioreactors systems have been proposed in bone 
tissue engineering, including spinner flasks [151-153], rotating wall bioreactors [154], and 
perfusion systems [155-158]. Spinner flask and rotating wall bioreactors are effective at 
creating a homogenous media solution surrounding the exterior, but do not effectively perfuse 
media into the interior of the scaffold. Perfusion systems effectively provide media (at 
laminar flow regimes) throughout the scaffold, enhancing nutrient transport. In addition, it 
exposes cells to fluid shear stresses shown to be influential in osteogenic differentiation of 
stem cells and mineralization of the extracellular matrix [159-160]. Indeed, in vivo bone 
constantly remodels in response to mechanical stresses and it was hypothesized that these 
stresses are mainly transmitted to bone cells via fluid shear stresses [161] and that they 
experience in vivo shears from 8 to 30 dynes/cm
2
 [162-163]. 
Mesenchymal stem cells (MSCs) are a multipotent stem cell population present in bone 
marrow, cartilage, and adipose tissue.  They are easily differentiated into osteoblasts, 
chondrocytes, or adipocytes [164-165]. Therapies involving MSCs include direct 
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transplantation of an MSC population, growth factor loaded scaffolds for MSC recruitment, or 
implantation of scaffolds containing an in vitro cultured MSC population [166-168]. During 
MSCs differentiation, biological and mechanical cues induce specific pathways dictating 
whether the cell remains multipotent or differentiates into a specific cell type. Recently, Yeatts 
et al. [169] demonstrated that human mesenchymal stem cells (hMSCs) can undergo 
osteoblastic differentiate into osteoblasts when cultured in the tubular perfusion system (TPS) 
bioreactor. The system cultures cell-encapsulated alginate bead scaffolds in a dynamic flow 
environment. It improves the supply of convective oxygen and nutrient transport within a 3D 
scaffold compared to static culturing conditions. In addition, it adds mechanical stimuli via 
the shear flow of the media, shown to improve osteoblastic differentiation. After in vitro 
culture, the beads can from an aggregated constructed for in vivo implantation. TPS flow rate 
was also optimized to apply a shear stress between 1 to 3 dynes/cm
2
.  
hMSCs respond favourably towards several biochemical signals. Particularly, it is 
reported that biopolymer scaffolds modified with growth factors (GFs) including fibroblast 
growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), or bone morphogenetic 
protein-2 (BMP-2) [170] could enhance in vivo bone growth. For example, VEGF, an 
angiogenic growth factor, has been used to enhance endothelial cell proliferation and 
encourage vessel sprouting aiding in the vascularization of an implanted construct [171-172]; 
whereas, BMP-2 has been widely investigated for its role in enhancing in vivo bone growth 
and in vitro osteoblastic signaling [173-176]. In this case, bioactive 3D scaffold capable of a 
locally controlled release of specific growth factors may provide an innovative tool capable of 
an additional level of cell environment regulation not possible with an inert scaffold.  
In this part of work, the TPS bioreactor was used to cultivate bioactive tissue-
engineered scaffolds, with the idea to provide in situ controlled release of GFs that will 
enhance differentiation of hMSCs not possible with an inert 3D scaffold. To provide proof of 
concept, bioactive alginate scaffolds were loaded with hMSCs and growth factor-encapsulated 
PLGA-PAMs (specifically h-VEGF and h-BMP-2) produced by SEE-C technology. Alginate 
was selected as a hydrogel because of the ease of spherical bead scaffolds formation and 
because they can been tightly packed in the TPS growth chamber.  The aim of this study was 
to determine the effect of different locally released GFs from PLGA-PAMs on the 
osteoblastic differentiation of hMSCs when cultured in alginate scaffolds in a dynamic TPS 
bioreactor. 
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5.2 Materials & Methods 
5.2.1 PLGA-PAMs production by SEE-C technology 
Water-oil-water emulsion ratio was fixed at 1:19:80. Particularly, a fixed amount of 
GFs was dissolved into a BSA solution with PVA concentration of 0.04% w/v and this 
solution was added into the oily phase of ethyl acetate (EA) and PLGA at 10% w/w. The 
primary w1-o emulsion was obtained upon 90 second sonication by digital ultrasonic probe at 
50% of amplitude (mod. S-450D, Branson Ultrasonics Corporation, Danbury, CT, USA). This 
primary emulsion was, then, immediately poured into a known amount of EA-saturated 
aqueous Tween 80 solution (0.6% w/w in water) used as outer water phase, to form the 
secondary emulsion by a high-speed homogenizer (mod. L4RT, Silverson Machines Ltd., 
Waterside, Chesham Bucks, United Kingdom) for 6 min at 10°C in an ice bath with a stirring 
rate of 2800 rpm. The emulsions were processed by SEE-C immediately. All the emulsions 
were prepared with filtered or autoclaved solutions.  
SEE-C apparatus was already described in detail in Chapter 2. Ultra filtered or 
autoclaved gas and liquids coupled with standardized GMP operative procedures in a 
continuous operation apparatus assured PAMs sterility (see also method section of Chapter 4). 
An additional PAMs passage in Pen/Strep (1% w/V) followed by washing in PBS was also 
performed. 
5.2.2 Morphology & size distributions 
The droplets formed in the emulsion were observed using an optical microscope (OM, 
mod. BX 50 Olympus, Tokyo, Japan) equipped with a phase contrast condenser. 
Microspheres shape and morphology were investigated by field emission-scanning electron 
microscopy (FE-SEM, mod. LEO 1525, Carl Zeiss SMT AG, Oberkochen, Germany). 
Samples of powder were placed on a double-sided adhesive carbon tape previously stuck to 
an aluminum stub and coated with a thin gold film (layer thickness 250Ǻ) using a sputter 
coater (mod.108 A, Agar Scientific, Stansted, United Kingdom). Droplet size distributions 
(DSD) and particle size distributions (PSD) were measured using a Mastersizer S apparatus 
(mod. Mastersizer S, Malvern Instruments Ltd., Worcherstershire, United Kingdom), based 
on the dynamic light scattering (DLS). Mastersizer S software uses Mie theory to produce an 
optimal analysis of the light energy distribution and to obtain the size distribution of the 
particles. Analyses were performed immediately after the preparation of the emulsions and of 
the microsphere suspensions, using several milligrams of each sample, appropriately diluted 
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with distilled water. The distributions proposed in this paper are the mean of several DLS 
analysis. Droplets and particle size are expressed as volume MS (mean size, µm) ± SD 
(standard deviation) of values collected.  
5.2.3 BSA & GFs release and loading 
The amount of BSA loaded into PAMs was determined by dissolving 10 mg of dried 
PAMs in 600 µL of acetonitrile in centrifuge tubes and sonicated until the of the solution  was 
complete transparency. Then, 1400 µL of water were added to the corresponding centrifuge 
tube to dissolve proteins and peptides. The remaining undissolved PLGA was separated by 
centrifugation at 2000 rpm for 2 minutes. The resulting clear supernatant solution was directly 
analyzed at room temperature by high-performance liquid chromatography (HPLC, mod. 
1200 series; Agilent Technologies Inc.) equipped with a LiCrosphere C18 column (250×4.6 
mm), packed with 5 µm particles size of 100 Å pore size. The mobile phase was composed of 
acetonitrile/water mixture. The flow rate was 0.9 mL/min, the inject volume of the test 
sampled was 20 µL and the detecting wavelength was 225 nm. The amount of BSA in 
solution was calculated by means of a calibration curve and then converted in the effective 
loading as the amount (mg) of protein charged in PLGA-PAMs (g). The BSA loading was 
assumed as a reference for the GFs loading.  
GFs release profiles were monitored in vitro using an ELISA-based assay. 20 mg of 
PLGA-PAMs were suspended in 2 mL of Dulbecco's Modified Eagle Medium (DMEM), in a 
centrifuge tube. The tubes were then placed in an incubator at 37°C and stirred continuously 
at 50 rpm. At fixed time intervals, the samples were centrifuged at 4000 rpm for 15 minutes 
and the supernatant was completely withdrawn and replaced with fresh medium to maintain 
sink conditions. Released VEGF concentrations from collected samples were then measured 
with an ELISA assay (PeproTech, Rocky Hill, NJ). Release experiments were performed in 
triplicate and the proposed curves are the mean profiles obtained. The percentage of released 
VEGF was defined as the mass of GFs released divided by the mass of the load. 
5.2.4 h-MSC Culture  
Human mesenchymal stem cells (p≤5) were purchased from Lonza (Walkersville, MD) 
and cultured before the study in a control medium containing High Glucose DMEM with L-
Glutamine (Gibco, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS, 
Invitrogen), 1% v/v penicillin/streptomycin (Gibco), and 0.1 mM nonessential Amino Acids 
(Invitrogen) following the protocol set by the manufacturer with a medium change every 4 
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days. Cells were stored in a cell culture incubator at 37°C and 5% of CO2 and passaged every 
6-7 days using tripsin/ethyldiaminetetraacetic acid (EDTA, Invitrogen). The osteogenic 
medium was formulated was formulated as described in the literature by supplementing 
control media with 100nM dexamethasone (Sigma, St. Louis, MO), 10mM b-
glycerophosphate and 173 mM ascorbic acid (Sigma) [177]. Cell samples were counted on a 
standard hemocytometer after their mixing with trypan blue (Sigma). Four counts were made 
for each sample. 
5.2.5 Alginate bead production loaded with PAMs and h-MSC 
2% w/w alginate solutions (Sigma Aldrich) were prepared by adding alginic sodium salt 
from brown algae (Sigma) dissolved into 0.15M NaCl (Sigma) and 0.025M HEPES (Sigma) 
in deionized water. The alginate solution was then sterilized via autoclave. hMSCs were 
removed from tissue culture flasks using trypsin/EDTA and pelleted via centrifugation at 500 
g for 5 min. The cell pellet was resuspended in HEPES buffer. Meanwhile, the GF-loaded 
PLGA-PAMs was also resuspended in HEPES buffer solution by sonification in ice water. 
PAMs/ HEPES suspension was poured into the sterile alginate solution and thoroughly stirred 
with a magnetic stir bar. Next, the cell suspension was added to the PAMs/alginate mixture 
and carefully stirred until fully integrated. A syringe and 16 1/2G needle were used to create 
the PAMs-hMSC-loaded alginate scaffold beads by a slow drop wise suspension into a stirred 
solution of 0.1M calcium chloride (Sigma), which immediately crosslinked the alginate to 
form beads. Beads were allowed to stabilize for 15 min. Roughly 100,000 hMSCs and 8 ug of 
growth factor were incorporated into each alginate bead. 
5.2.6 Perfusion Bioreactor for Dynamic Environment 
The tubular perfusion bioreactor (TPB, see Images on Figures 5.1a-b) bioreactor was 
used as a dynamic fluid conditioner. It consists of a tubular growth chamber and medium 
reservoir connected via a tubing circuit, as described in a previous work [178]. The medium’s 
flow was driven by an L/S Multichannel Pump System (Cole Parmer, Vernon Hills, IL) at 3 
mL/min. The circuit consists of platinum-cured silicone tubing (Cole Parmer) connected using 
silver ion-lined connectors (Cole Parmer). The growth chamber has high gas permeability to 
allow for easy exchange of carbon dioxide and oxygen and is made of platinum-cured silicone 
tubing (Cole Parmer) with an inner diameter of 6.4 mm, an outer diameter of 11.2 mm and a 
wall thickness of 2.4 mm and. After loading, the autoclaved tubing was fully assembled inside 
a cell culture hood and then placed in a cell culture incubator at 37C and 5% CO2. 70 mL 
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milliliters of the osteogenic medium were loaded into separate flasks for each growth 
chamber. The medium was withdrawn and replaced every 4 days. Briefly, the beads were 
divided into four different groups, depending on their GFs loaded PAMs and placed into four 
growth chambers. At each experimental timepoint, beads residing in the top most chambers 
were removed for further analysis and the empty chamber replaced.  
 
(a) (b) 
Figure 5.1a-b. Schematic representation of the bioactive scaffold charged in a tubular bioreactor (a). 
Image of the bioreactor with the four chambers (b).   
 
5.2.7 Static Environment 
As a control, beads were also placed into a static environment. The same number of 
beads was incubated at 37°C, 5% CO2 in 6-well plates with 1mL of osteogenic media per 
bead. Analysis was carried out on the static beads on the same time points.  
5.2.8 Immunohistochemistry 
At different time points of culture (1, 7, 21 days) alginate beads were recovered from 
dynamic and static culture conditions. They were fixed in 4% paraformaldehyde (Sigma) for 3 
hours, followed by an overnight incubation in sodium cacodylate (Sigma). The beads were 
then placed in casettes and dehydrated for histological processing in a series of ethanol 
dilutions (75%, 90%, 100%). The samples were then embedded in paraffin (Fisher Scientific), 
sectioned using a Microtom (Lica) into 5-micron-thick sections and placed on glass slides 
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(Fisher Scientific). The samples were deparaffinized in Ctrisolv (Fisher Scientific) and 
rehydrated in ethanol.  
Specifically, osteoblastic differentiation was monitored using immunohistological 
staining of protein markers, including alkaline phosphatase (ALP), an early differentiation 
marker, and osteocalcin (OCN) and osteopontin (OPN), both late differentiation markers. 
Generally, the samples underwent standard immunostaining protocol for antigen retrieval, 
endogenous peroxidase and protein blocks. They were incubated for an hour with rabbit 
monoclonal ALP, mouse monoclonal osteocalcin, mouse monoclonal osteopontin (AbCam, 
Cambridge, MA), respectively, followed by broadband polyclonal biotinylated secondary 
antibody (Abcam, Cambridge, MA).  
For the von Kossa staining of the sections, the samples were incubated inin 2.5% (w/v) 
silver nitrate for 20 min under UV light, followed by 5% (w/v) sodium carbonate for 5 min, 
and 0.1% Nuclear Fast Red (Poly Scientific). Lastly, the samples were dehydrated again in the 
same series of ethanol dilutions. 
5.2.9 Live-dead assay 
Cell viability was assessed using a live-dead assay (Invitrogen) following standard 
protocols. Beads were first soaked in PBS for 60 min to remove FBS and the medium. Dead 
controls were soaked in 70% methanol (Sigma) instead of PBS. Beads were then placed in 48-
well plates and incubated in 2 mm ethidium homodimer and 4 mm calcein AM (Molecular 
Probes) for 30 min. Fluorescent images were then taken of the entire bead using a fluorescent 
microscope (Axiovert 40 CFL with filter set 23; Zeiss, Thornwood, NY) equipped with a 
digital camera (Diagnostic Instruments 11.2 Color Mosaic, Sterling Heights, MI). Live-dead 
images of whole beads, not cross sections, were obtained. 
5.2.10 Statistical Analysis 
All samples were completed in triplicate. Data were analyzed using single-factor 
analysis of variance followed by Tukey’s Multiple Comparison Test assuming normal data 
distribution with a confidence of 95% ( p<0.05). Mean values of triplicates and standard 
deviation error bars are reported on each figure as well as relevant statistical relationships. 
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5.3 Results & Discussion 
5.3.1 SEE-C operative conditions for PLGA-PAMs manufacturing 
The SEE-C pressure and temperature conditions in the high pressure column were of 8 
MPa and 38°C with an SC-CO2 flow of 1.4 kg/h and an L/G ratio of 0.1; these conditions 
were used because already optimized, as discussed in Chapter 2. At these SEE-C conditions 
the processed emulsions were converted in a PLGA-PAMs water suspension in less than 5 
min of residence time in the column, preventing any aggregation phenomena between 
particles. Each run allowed the recovery of the 98% of the charged biopolymer and assured an 
excellent batch to batch reproducibility. 
5.3.2 PLGA-PAMs: size, loading & in vitro GFs release study 
Four w1-o-w2 double emulsions (see “Apparatus, Materials and Methods” section for the 
exact composition) with a fixed PLGA content in the oily phase of 10% w/w and GFs 
theoretical loading of 10 ug/g were prepared. BSA was always used as GFs stabilizer in the 
emulsion internal water phase with a concentration of 2.5 mg/g of PLGA. Droplets with a 
MDs of 3 µm (± 0.9 µm) were always obtained and processed by SEE-C just after their 
preparation producing four batches of PAMs with a MDs of 2.1 µm (± 0.6 µm). In all cases, 
the droplets shrunk almost 30% in diameter. Examples of results obtained are reported in 
Figures 5.2a-d, depicting optical microscopy (OM) images of the emulsions treated and FE-
SEM images of the related PAMs. Four different batches were produced for the present study: 
B1, only BSA- but no growth factor-loaded PAM; B2, BSA- and hBMP-2-loaded PAM; B3, 
BSA and hVEGF-loaded PAM; and B4, BSA- an 50:50 mix of hBMP-2 and hVEGF-loaded 
PAM. hBMP-2 was selected because it plays an important role in development of bone and 
cartilage and has been found to be involved in inducing osteogenesis; whereas VEGF is 
traditionally known to stimulate vasculogenesis and angiogenesis and is also secreted during 
osteoblastic differentiation. 
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Figure 5.2a-d. Optical microscope (OM) images of emulsion and FE-SEM image of the microspheres 
obtained by SEE-C. B1, only BSA charged PAMs; B2, BSA and h-Bone Morphogenic Protein 2 (h-BMP-
2) charged PAMs; B3, BSA and h-Vascular Endothelial Growth Factor (h-VEGF) PAMs; B4, BSA and 
GFs mix (ratio 1:1) charged PAMs. 
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The PSD curves of the four different PLGA-PAMs batches are illustrated in Figure 5.3; 
their overlapping confirms the high reproducibility of the SEE-C technology for the 
production of nanostructured microdevices. In all cases, the BSA encapsulation efficiency 
was 80%, leading to the production of PLGA-PAMs with a protein content of 2 mg/g of 
PLGA. As a consequence, the GF loading was assumed to be 8 ug/g of PLGA. The release 
profile of GFs from PAM was monitored in DMEM medium is reported in Figure 5.4. A 
burst almost the 20% of the GF was observed during the first day, followed by a more gradual 
and linear release over the following 16 days. The entire amount of GF was released within 22 
days, so the encapsulated GFs in alginate bead scaffolds will provide a good in situ GF 
delivery to the onboard hMSCs for 20 days..  
5.2.3 Scaffold characterization and bioreactor conditions 
100 alginate beads with a mean diameter of 0.46 mm were produced per experimental 
group (hVEGF, hBMP2, and 50:50 mix of each). Each bead was loaded with 100,000 hMSCs 
and 8 ug of GF-encapsulated PAM. Therefore, an average amount of 80 ng of hBMP2 or 
hVEGF were encapsulated into each beads for the groups B2 and B3, respectively. However, 
40 ng of each GFs were present into the bead belonging to B4 group.  
A schematic representation of the bioactive scaffold is shown in Figure 5.5a. A 
viability stain was performed on the bead at the end of the cultivation period as seen in Figure 
5.5b, where green represents live cells and red stains dead cells. Figures 5.6a-b shows two 
different enlarged sections of the alginate beads after hematoxylin and eosin (H&E) staining 
as observed using a phase-contrast condenser. In the two images, it is evident that the hMSCs 
(pink) and the PAMs (white spots) are uniform distributed in the alginate matrix.  
The internal structure of a freeze-fractured scaffold was also confirmed using SEM at 
different enlargements, as seen in Figures 5.7a-c. Particularly in Figure 5.7b, it is evident 
that the PAM is uniformly distributed in the alginate matrix, while a single hMSC is 
highlighted by a red circle in Figure 5.7c. 
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Figure 5.3. Particle Size Distribution curves of the PAMs produced by SEE-C; the size distribution curve 
of the droplets in emulsion is also reported in grey, for comparison purpose. 
 
 
Figure 5.4. Release profiles (days) of GFs from PLGA-PAMs suspended in DMEM medium. 
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a. 
 
b. 10 X 
 
Figure 5.5a-b. A schematic representation of the bioactive scaffold with the PAMs (green), the cells 
(yellows and red) and the alginate gel (pink) (a); live & dead image of part of a bead taken from 28 days of 
cultivation with an enlargement of 10 X; the PAMs were stained in red (b). 
 
a. 2.5 X b. 40 X 
 
Figure 5.6a-b. OM images of alginate beads sections reported with two different enlargements; sections of 
the alginate beads after Hematoxylin and Eosin staining observed at optical microscope with a phase 
contrast condenser; in the two images are evident the h-MSC in pink and the PAMs (as a white spots) 
uniformly distributed in the alginate matrix. 
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1000X  
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3000X  
Figure 5.7a-c. FE-SEM images at different enlargements of the alginate beads fractured after its freezing 
in liquid nitrogen. PAMs are uniformly distributed in the gel matrix. The h-MSC is highlighted by a red 
circle. 
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Beads of each group were packed into four different TPS growth chambers. Each 
growth chamber was set to have an internal volume of 9 cm
3
 and was charged with 60 beads 
(with a volume of 0.05 cm
3
 each) in order to have an equivalent CSTR volume of 6 cm
3
 and a 
packing density of 0.33. Separate flasks each containing 60 mL of the osteogenic media were 
connected to the chambers and a volume of 0.1 mL of medium was calculated for each bead. 
A continuous flow rate of 3 mL/min provided media to the cells throughout the study, with 
ostegenic media changed every 4 days. In these conditions, a Sherwood number (that 
represent the ratio between the convective to diffusive mass transfer) of 13 was assured into 
the TPS bioreactor, as calculated in a previous study. The bioreactor was kept at a sterile 37°C 
incubator with 5% CO2. As a control, beads were also incubated at static conditions in 6-well 
plates with the same volume of osteogenic media per bead. To determine flow velocities and 
calculate shear stresses a 2D steady-state Navier-Stokes model was used by COMSOL 
Multiphysics Ver. 3.5. Initial flow into the growth chamber was modeled assuming fully 
developed flow. Walls of alginate beads were modeled as no slip and the medium was 
assumed to have a dynamic viscosity of 0.78 centipoise and a density of 0.993 g/cm
2
. 
Boundary shear stresses were calculated using the formula =  (v/y), where  is the 
dynamic viscosity of the media, v is the velocity of fluid at the bead surface and y is the 
height of the boundary layer [179]. Based on the mathematical analysis the average shear 
stress at the surface of the beads in this study was of 0.98 (±0.08) dyn/cm
2 
for the 3 mL/min 
flow. For long-term culture in the bioreactor, shear stresses of 0.15 dyn/cm
2
 have been 
reported to enhance osteoblastic differentiation [180].  
5.3.4 Immunoassay for cell differentiation monitoring 
Alginate beads were recovered from dynamic and static culture at different time points 
(days 1, 7 21 and 28). At each experimental time point, beads were removed for 
immunostaining analysis and the empty chambers replaced. The following proteins were 
stained to monitor cells differentiation: alkaline phosphatase, osteocalcin, and osteopontin. In 
addition, von Kossa staining was used to study mineralization and calcification of the cells.  
Figures 5.8a-d shows OM images of beads after immunostaning for ALP of all the four 
experimental groups on day 7. ALP is considered an early osteogenesis marker and is 
involved in making inorganic salts available for later calcification. Its peak expression occurs 
between day 6 and 8 of culture. Cross-sectional images of alginate scaffolds revealed strong 
ALP activity in cell clusters formed in beads when cultured with hBMP-2. ALP expression 
 99 
was also observed in beads belonging to the B4 group (both hBMP2 and hVEGF). However, 
in this case, less cell clustering were observed. Less evident protein activity was observed on 
day 7 in the bioactive scaffolds containing hVEGF and in the scaffolds contained the empty 
PLGA-PAM (control group). 
Figures 5.9a-d shows osteopontin (OPN) staining completed for all the four groups on 
day 21. OPN is a cellular structural protein in mature osteoblast produced between days 14 
and 28 and represents late osteoblastic differentation. Cross-sectional images of alginate 
scaffolds revealed substational OPN activity in beads belonging to the B2 group (hBMP-2) on 
day 21, whereas, this protein was clearly stained into the group B4, only later at days 28
th
.  
Figures 5.10a-d show osteocalcin (OCN) staining completed for all four groups on day 
21. OCN is also considered marker of late osteogenic maturation that is produced between 
day 14 and 28. The images revealed a strong production of OCN and further confirmed the 
formation of cell clusters in the beads belonging to the B2 group (hBMP-2). OCN activity 
was also observed in B4 group, but less cell clusters were again observed. Low expression of 
OCN was observed in the bioactive scaffolds containing hVEGF and empty PAM (control 
group), on the same day. Figures 5.11a-d depict OM cross-sectional images of beads 
cultivated until day 21 and stained with von Kossa to observe the calcium deposition by 
hMCSs in the scaffolds. Images from day 21 demonstrated that the calcium deposition 
occurred in all experimental groups. However, a more homogeneous and intense calcium 
deposition was observed in the beads loaded with hBMP-2 encapsulated PAM. 
The immunostaining assays confirmed that osteoblastic differentiation of hMSCs was 
enhanced in the bioreactor compared to when cultured in static conditions and revealed that 
hBMP-2 released in alginate scaffolds has a great influence of the on hMSC differentiation. In 
this sense, hBMP-2 sustained released and TPS cultivation may have a synergistic effect on 
hMSC differentiation; indeed due to their encapsulation in the alginate, only a portion of the 
cell population is exposed to the shear that could be too low to influence early differentiation, 
but may be high enough to affect late term differentiation and matrix deposition.  
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Figure 5.8a-d. Alkaline phosphatase staining of alginate beads after 7
 
days of culture in a TPS. All the 
images are made with the 40 X objective. B1, empty; B2, h-BMP-2; B3, h-VEGF; B4, GFs mix (ratio 1:1). 
ALP activity is marked in brown and appeared well stained in the group B2 and B4, revealing a great 
influence of h-BMP-2 released into the scaffold on the earlier cell differentiation.  
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Figure 5.9a-d. Osteopontin (OPN) staining of alginate beads after 21
 
days of culture in a TPS. All the 
images are taken using a 40 X objective. B1, empty; B2, h-BMP-2; B3, h-VEGF; B4, GFs mix (ratio 1:1). 
OPN activity is marked in brown and appeared well stained in the group B2 and B4.  
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Figure 5.10a-d. Osteocalcin (OCN) staining of alginate beads after 21
 
days of culture in a TPS. All the 
images are taken using a 40 X objective. B1, empty; B2, h-BMP-2; B3, h-VEGF; B4, GFs mix (ratio 1:1). 
OCN activity is marked in brown and appeared well stained in the group B2 and B4, confirming the great 
influence of h-BMP-2 released into the scaffold on the earlier cell differentiation.  
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Figure 5.11a-d. Von Kossa staining of alginate beads after 21 of culture in a TPS. All the images are taken 
using a 40 X objective. B1, empty; B2, h-BMP-2; B3, h-VEGF; B4, GFs mix (ratio 1:1). The calcium 
deposition started into the scaffolds belonging to all groups; however, a more homogeneous calcium 
deposition was always observed in the beads charged with PAMs able to release h-BMP-2 growth factors. 
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5.4 Conclusion & Perspectives 
Bioactive scaffolds charged with GFs can be complementary to mechanical stress, by 
improving from biochemical point of view an earlier cell differentiation. 
Histology results showed dynamic cell culturing significantly impacted osteogenic 
hMSC differentiation compared to those cultured in static conditions. In addition, those cells 
supplemented with growth factor-loaded PLGA microspheres had increased expression of 
osteogenic markers as compared to those cultured with empty microspheres. Specifically, 
cells exposed to BMP-2 produced greater amounts of ALP, OCN and OPN for all three time 
points, as evident in the darker and more intense staining, compared to the unloaded 
microsphere control group. VEGF had the least visible effect on osteogenic marker 
expression, although still greater than the control. In addition, histology indicated that mixed 
growth factor supplement had comparable osteogenic effects on the hMSCs as the BMP-2 
growth factor alone, further confirming VEGF’s limited impact.  
Lastly, ELISAs showed sustained growth factors released from microspheres over a 21-
day period confirming continuous diffusion to cells; i.e., SEE is a suitable fabrication method 
of PLGA microspheres to provide sustained release of growth factors. Hence, dynamic flow 
culturing environment in the TPS bioreactor and sustained-release growth factors from PLGA 
microspheres show to have a synergistic effect on osteogenic differentiation of hMSCs. 
Future studies will include optimization of the BMP-2 dose delivered to hMSCs.  
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Conclusions & Perspectives 
 
Supercritical fluids Emulsion Extraction (SEE) technology offers a new strategy in the 
biopolymer microsphere production with a better particle size control and excellent 
encapsulation efficiency. In this PhD work an innovative SEE apparatus, operating in 
continuous layout (SEE-C), was developed by using a high pressure packed column in 
counter-current mode. Process parameters such as, pressure, temperature, high pressure phase 
compositions and flow rate ratios were optimized for the production of PLGA microdevices 
with a controlled sizes and engineered nanostructure. Taking advantage of the enhanced mass 
transfer of the supercritical solvent, biopolymer microcarriers were successfully produced 
with excellent encapsulation efficiency. Moreover, the upgrade of the SEE technology into 
the continuous process allowed a higher throughput with smaller plant volumes, eliminating 
all the batch-to batch repeatability problems. This technology was tested for the production of 
PLGA microdevices to be used in the cell therapy, as a major therapeutic strategy for some 
specific tissue regeneration. PLGA carriers charged with different bioactive compounds were 
produced and characterized in terms of bioactive principle encapsulation efficiencies and 
release profiles. An attempt of diffusion and degradation constants calculation was also 
performed by using a mathematical model selected from the literature. 
PLGA microcarriers charged with bovine serum insulin were tested for the cultivation 
of embryonic myoblasts (cell line H9c2 from rat) in a FBS serum free medium. Good cell 
viability and growth were observed on 3 µm PAMs charged with 3 mg/g of insulin. PLGA 
microcarriers loaded with different growth factors such as h-VEGF and h-BMP-2 were also 
charged inside an alginate scaffold together with h-Mesenchimal Steam Cells (h-MSC) that 
are promising cell source for bone tissue engineering. BMP-2 showed to have a dominant 
effect on osteogenic marker production compared to VEGF in both static and dynamic 
conditions, indicating that it is an important growth factor in the differentiation pathway. 
Hence, dynamic flow culturing environment in the tubular perfusion system bioreactor and 
sustained-release growth factors from PLGA microspheres shown to have a synergistic effect 
on osteogenic differentiation of hMSCs. Future studies will include optimization of the BMP-
2 dose delivered to h-MSCs. 
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